<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="jocd16707" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cosmet Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">J Cosmet Dermatol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1473-2165</journal-id><journal-id journal-id-type="publisher-id">JOCD</journal-id><journal-title-group><journal-title>Journal of Cosmetic Dermatology</journal-title></journal-title-group><issn pub-type="ppub">1473-2130</issn><issn pub-type="epub">1473-2165</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39731267</article-id><article-id pub-id-type="pmc">PMC11680975</article-id><article-id pub-id-type="doi">10.1111/jocd.16707</article-id><article-id pub-id-type="publisher-id">JOCD16707</article-id><article-id pub-id-type="other">JCD-08-2024-888.R1</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Review of Applications of Microneedling in Melasma</article-title></title-group><contrib-group><contrib id="jocd16707-cr-0001" contrib-type="author"><name><surname>Chen</surname><given-names>Wenwen</given-names></name><xref rid="jocd16707-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jocd16707-cr-0002" contrib-type="author"><name><surname>Jian</surname><given-names>Xingling</given-names></name><xref rid="jocd16707-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jocd16707-cr-0003" contrib-type="author" corresp="yes"><name><surname>Yu</surname><given-names>Bo</given-names></name><xref rid="jocd16707-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>yubomd@163.com</email></address></contrib></contrib-group><aff id="jocd16707-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Medicine</named-content>
<institution>Shandong Second Medical University</institution>
<city>Weifang</city>
<country country="CN">China</country>
</aff><aff id="jocd16707-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Dermatology</named-content>
<institution>Peking University Shenzhen Hospital</institution>
<city>Shenzhen</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Bo Yu (<email>yubomd@163.com</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2025</year></pub-date><volume>24</volume><issue seq="30">1</issue><issue-id pub-id-type="doi">10.1111/jocd.v24.1</issue-id><elocation-id>e16707</elocation-id><history>
<date date-type="rev-recd"><day>04</day><month>11</month><year>2024</year></date>
<date date-type="received"><day>12</day><month>8</month><year>2024</year></date>
<date date-type="accepted"><day>19</day><month>11</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 Wiley Periodicals, Inc.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">Journal of Cosmetic Dermatology</italic> published by Wiley Periodicals LLC.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JOCD-24-e16707.pdf"/><abstract><title>ABSTRACT</title><sec id="jocd16707-sec-0001"><title>Background</title><p>Melasma, a common skin pigmentation disease, can negatively impact patients' mental health, social interactions, and physical appearance. Although we now have several treatments accessible, such as medicines, chemical peels, and phototherapy, which can help ease symptoms to some extent, the requirement for a long&#x02010;term effective and safe treatment for patients is far from met. In the face of this problem, microneedling, as an innovative treatment, provides a new avenue for treating melasma. Although microneedling has been extensively investigated for treating other skin issues such as inflammation, scarring, and photoaging, research into its use in melasma treatment is still in its early stages.</p></sec><sec id="jocd16707-sec-0002"><title>Objective</title><p>This study aimed to gather and assess clinical information on microneedling's effectiveness in treating melasma, covering research gaps and serving as a beneficial reference for clinical therapy.</p></sec><sec id="jocd16707-sec-0003"><title>Methods</title><p>We searched PubMed, Cochrane, Scopus, Embase, and Web of Science databases for articles with the keywords &#x0201c;microneedling,&#x0201d; &#x0201c;percutaneous collagen induction&#x0201d;, and &#x0201c;melasma.&#x0201d; Following a thorough assessment, we selected 64 clinical studies that matched the requirements for in&#x02010;depth analysis.</p></sec><sec id="jocd16707-sec-0004"><title>Results</title><p>After thoroughly reviewing these data, we concluded that microneedling has tremendous potential for treating melasma. Microneedling can significantly improve treatment outcomes, especially when paired with additional therapies such as topical medicines or phototherapy.</p></sec><sec id="jocd16707-sec-0005"><title>Conclusion</title><p>Overall, the evidence reported in this study demonstrates that microneedling is an essential advancement in melasma treatment. Not only can it improve the efficacy of topical drugs and other treatment modalities, but it also has an excellent safety and tolerability profile, making it desirable to patients and clinicians. While the current findings are encouraging, more study is needed to refine treatment protocols, investigate the long&#x02010;term consequences of microneedling, and establish it as the standard of care for melasma treatment. We anticipate that microneedling will play an increasingly important role in the future of melasma treatment, providing our patients with more hope and a broader choice of treatment alternatives.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jocd16707-kwd-0001">application</kwd><kwd id="jocd16707-kwd-0002">melasma</kwd><kwd id="jocd16707-kwd-0003">microneedle</kwd><kwd id="jocd16707-kwd-0004">review</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Shenzhen Science and Technology Commission Project</funding-source><award-id>JYC20220531094008019</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Sanming Project of Medicine in Shenzen Municipality
</institution><institution-id institution-id-type="doi">10.13039/501100012151</institution-id></institution-wrap></funding-source><award-id>SZSM202311029</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>National Natural Science Foundation of China
</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>81673053</award-id></award-group></funding-group><counts><fig-count count="0"/><table-count count="3"/><page-count count="16"/><word-count count="10200"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:28.12.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="jocd16707-ntgp-0001"><fn fn-type="funding" id="jocd16707-note-0001"><p>
<bold>Funding:</bold> This study was supported by National Natural Science Foundation of China (No. 81673053), Shenzhen Sanming Project (No. SZSM202311029) and Shenzhen Science and Technology Commission Project (JYC20220531094008019).</p></fn></fn-group></notes></front><body id="jocd16707-body-0001"><sec id="jocd16707-sec-0006"><label>1</label><title>Introduction</title><p>Melasma, a skin pigmentation condition that affects people's physical appearance, can also cause psychological problems, including anxiety and sadness. Consequently, melasma management and treatment are significant challenges for the medical community and the general public. Among Asian women of childbearing age, melasma prevalence is 30% [<xref rid="jocd16707-bib-0001" ref-type="bibr">1</xref>]. Melasma, which has a complex etiopathogenesis and is multifactorial, has a wide range of clinical symptoms and histological features [<xref rid="jocd16707-bib-0002" ref-type="bibr">2</xref>]. Although there are many melasma treatments, including chemical peel therapy, phototherapy, systemic medication therapy, and cosmetic therapy, their long&#x02010;term safety and efficacy are yet to be tested. Researchers are investigating new ways of overcoming current treatment limitations, such as via the development of targeted topical components, combined phototherapy, and combining microneedle therapy and pharmaceutical medications.</p><p>Microneedling therapy, also known as percutaneous collagen induction therapy, is a new treatment that encourages the growth of collagen tissue in the skin by physical or mechanical methods. This therapy uses a device with many fine needles to create micropunctures on the skin, promoting collagen regeneration. This approach preserves the epidermis' integrity and considerably improves the percutaneous absorption of therapeutic drugs, providing good clinical results in the treatment [<xref rid="jocd16707-bib-0003" ref-type="bibr">3</xref>]. Microneedle therapy, initially known as &#x0201c;incision,&#x0201d; was developed by Orentreich et&#x000a0;al. [<xref rid="jocd16707-bib-0004" ref-type="bibr">4</xref>] for scar and wrinkle healing. However, it is inappropriate for extensive face rejuvenation or treating minor body areas. Dr. Desmond Fernands pioneered a unique procedure, whereby the skin is continuously pierced with a drum&#x02010;shaped device equipped with many tiny needles, which preserves the epidermis while promoting collagen renewal [<xref rid="jocd16707-bib-0005" ref-type="bibr">5</xref>]. This breakthrough accelerated microneedle therapy development, leading to various products, including motorized, radiofrequency, and nano microneedles [<xref rid="jocd16707-bib-0006" ref-type="bibr">6</xref>]. Moreover, because of its low cost and minimal invasiveness, microneedle therapy has the potential for use in dermatological and cosmetic treatments.</p><p>Although traditional melasma treatments like hydroquinone are considered safe and effective, their therapeutic potential is limited by many factors, such as sluggish onset and poor patient compliance. Their long&#x02010;term use may also have adverse side effects, including dryness, peeling, and uneven skin pigmentation, highlighting the need for alternative treatments [<xref rid="jocd16707-bib-0007" ref-type="bibr">7</xref>]. Here, based on the most recent research findings, we assess the full use of microneedle therapy on patients with melasma and offer an overview of various microneedling types, their potential therapeutic mechanisms against melasma, and their real&#x02010;world clinical uses.</p></sec><sec sec-type="methods" id="jocd16707-sec-0007"><label>2</label><title>Methods</title><p>Covering the period from database creation to May 2024, literature searches were performed on PubMed, Cochrane, Scopus, Embase, and Web of Science databases for papers on microneedling use for melasma treatment. Additional relevant data were obtained from the reference lists of the included publications. The search criteria included the MeSH phrases (microneedle* or microneedling or &#x0201c;skin needling&#x0201d; or percutaneous collagen induction or micro needling or dermapen or dermaroller or &#x0201c;dermal needling&#x0201d; or needling or &#x0201c;needling, skin&#x0201d; or collagen induction, percutaneous) AND (melasma* or chloasma* or melanosis or melanism* or freckle* or melanoses), adjusted accordingly in each database. Only articles published in English were included. Included clinical investigations involved the use of microneedles alone, microneedle use in combination with medication (oral, topical, andinjectable) or as a multimodal treatment component, and comprehensive accessible data involving human participants. This review is based on a large corpus of literature and for a thorough analysis, 64 significant microneedle and melasma datapoints were extracted.</p></sec><sec sec-type="results" id="jocd16707-sec-0008"><label>3</label><title>Results</title><sec id="jocd16707-sec-0009"><label>3.1</label><title>Study Selection</title><p>A thorough literature search involving keywords and free&#x02010;text queries yielded 629 results. The screening procedure, which strictly adhered to the established inclusion and exclusion criteria, identified 80 articles for initial evaluation. After a thorough review, eight studies that used facial acupuncture or acupuncture to specifically treat melasma, seven that used mesodermal therapy to manage melasma, and one that lacked complete text, were excluded. Finally, 64 publications were selected for comprehensive review.(See Tables&#x000a0;<xref rid="jocd16707-tbl-0001" ref-type="table">1</xref>, <xref rid="jocd16707-tbl-0002" ref-type="table">2</xref>, <xref rid="jocd16707-tbl-0003" ref-type="table">3</xref> for details).</p><table-wrap position="float" id="jocd16707-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Single microneedle treatment.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Reference</th><th align="center" valign="bottom" rowspan="1" colspan="1">Microneedle type</th><th align="center" valign="bottom" rowspan="1" colspan="1">Number of subjects</th><th align="center" valign="bottom" rowspan="1" colspan="1">No of sessions (interval)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Treatments</th><th align="center" valign="bottom" rowspan="1" colspan="1">Results</th><th align="center" valign="bottom" rowspan="1" colspan="1">Side effects</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Cassiano et&#x000a0;al. [<xref rid="jocd16707-bib-0022" ref-type="bibr">22</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dr. Roller, 1.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">20 females</td><td align="center" valign="top" rowspan="1" colspan="1">before/after 7&#x02009;days</td><td align="center" valign="top" rowspan="1" colspan="1">MN for full face</td><td align="center" valign="top" rowspan="1" colspan="1">MN significantly reduced melanin density, prolapsed melanocytes, and basement membrane damage in tissues</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Taher, El&#x02010;Sayed and Bessar [<xref rid="jocd16707-bib-0023" ref-type="bibr">23</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermapen</td><td align="center" valign="top" rowspan="1" colspan="1">17 females</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Right side: MN</p>
<p>Left side: Placebo</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Compared with placebo, MN alone had a significant whitening effect with satisfactory results</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Park et&#x000a0;al. [<xref rid="jocd16707-bib-0092" ref-type="bibr">92</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">RF,1.0&#x02013;1.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">25 patients</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">RF for full face</td><td align="center" valign="top" rowspan="1" colspan="1">RF could be a treatment option for facial pigmentary disorders</td><td align="center" valign="top" rowspan="1" colspan="1">Mild erythema, edema, pain</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wu et&#x000a0;al. [<xref rid="jocd16707-bib-0025" ref-type="bibr">25</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">MFRS, 1.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">Nine patients</td><td align="center" valign="top" rowspan="1" colspan="1">2 (3&#x02009;months)</td><td align="center" valign="top" rowspan="1" colspan="1">MFRS for full face</td><td align="center" valign="top" rowspan="1" colspan="1">MRFS therapy did not lead to hyperpigmentation or aggravated melasma in patients with or without melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Erythema, edema, or purpura</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Markowitz [<xref rid="jocd16707-bib-0030" ref-type="bibr">30</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">RF with Profondmartrix Systham</td><td align="center" valign="top" rowspan="1" colspan="1">Two patients</td><td align="center" valign="top" rowspan="1" colspan="1">3 (6&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">RF for full face</td><td align="center" valign="top" rowspan="1" colspan="1">The device can significantly reduce the density of blood vessels in the skin of melasma patients</td><td align="center" valign="top" rowspan="1" colspan="1">No adverse effects were observed</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Han et&#x000a0;al. [<xref rid="jocd16707-bib-0029" ref-type="bibr">29</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">RF, 0.3, 0.8&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">11 females</td><td align="center" valign="top" rowspan="1" colspan="1">12 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">After 4&#x02009;weeks of oral TA&#x02009;+&#x02009;triple cream, randomized to left or right side for radiofrequency treatment</td><td align="center" valign="top" rowspan="1" colspan="1">The continuous RF is beneficial in maintaining the conventional therapy of melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Mild erythema and pain</td></tr></tbody></table><table-wrap-foot id="jocd16707-ntgp-0002"><fn id="jocd16707-note-0002"><p>Abbreviations: MFRS, microneedle fractional radiofrequency system; MN, microneedling; RF, radiofrequency; TA, tranexamic acid.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jocd16707-sec-0010"><label>3.2</label><title>Study Characteristics</title><p>This review provides a complete overview of the included studies, including treatment cycles, the number of treatment sessions, device type, and treatment adverse events. The 64 studies included in this review involved &#x0003e;&#x02009;1000 patients with melasma and of these, &#x0003e;&#x02009;90% were female, indicating that melasma is more prevalent among women. The microneedle devices used in the included studies were mainly Demaroller (the most popular microneedle instrument worldwide), Dermapen, or their variants. Needle lengths ranged from 0.25 to 2&#x02009;mm, indicating that although microneedle device types for melasma treatment are relatively constant, needle lengths vary broadly, allowing for personalized selection based on individual patient needs. The studies' treatment cycles varied widely, with the number of treatment sessions and the time between treatments ranging from 1&#x02013;12 to 0&#x02013;4&#x02009;weeks, respectively, highlighting the importance of individualized treatment based on unique patient characteristics and reactions. The clinical studies that used microneedling for melasma reported erythema and discomfort as the most common side effects. However, the prevalence of serious adverse responses was low, implying that although some side effects may occur during treatment, they are often tolerable to patients. The included studies offer crucial clinical insights that provide the foundation for future melasma treatment research.</p></sec></sec><sec sec-type="discussion" id="jocd16707-sec-0011"><label>4</label><title>Discussion</title><sec id="jocd16707-sec-0012"><label>4.1</label><title>Microneedling Tools</title><p>The microneedling market has markedly grown because of advancements in medical and cosmetic technology, giving rise to a wide variety of microneedling products that fall into the following main categories: dermaroller, dermapen, and combined&#x02010;type microneedling devices (radiofrequency microneedling, LED microneedling, and the microneedle drug delivery system) [<xref rid="jocd16707-bib-0008" ref-type="bibr">8</xref>, <xref rid="jocd16707-bib-0009" ref-type="bibr">9</xref>, <xref rid="jocd16707-bib-0010" ref-type="bibr">10</xref>, <xref rid="jocd16707-bib-0011" ref-type="bibr">11</xref>, <xref rid="jocd16707-bib-0012" ref-type="bibr">12</xref>]. The characteristics of microneedle products vary from company in features, including material composition, needle diameter, length, and structural design.</p><p>We discovered that more researchers preferred the dermaroller to alternative microneedling products due to the following factors:
<list list-type="order" id="jocd16707-list-0001"><list-item id="jocd16707-li-0001"><p>Easy to use: The dermaroller is a manually operated microneedling device that allows the doctor or user to adjust the angle, force, and depth based on the individual's skin condition and comfort level, as well as the various treatment areas, particularly in sensitive areas like the eyes, nose, and lips. This personalized approach is ideal for individuals seeking a tailored treatment plan. Dermapen and combined&#x02010;type microneedling devices, on the other hand, necessitate more complex operation and setup and may require the assistance of specialized professionals. Furthermore, the dermaroller's handle is ergonomically built for a secure grip, reducing hand fatigue and increasing user comfort, this design makes it more flexible and easier to use during therapy.</p></list-item><list-item id="jocd16707-li-0002"><p>Flexibility in treatment: Dermaroller offers microneedle lengths ranging from 0.1 to 3.0&#x02009;mm, including CIT&#x02010;8TM (0.5&#x02009;mm), MF8TM (1.5&#x02009;mm), MF&#x02010;4 (1.5&#x02009;mm), and Beauty Mouse (0.2&#x02009;mm) for home care [<xref rid="jocd16707-bib-0006" ref-type="bibr">6</xref>, <xref rid="jocd16707-bib-0008" ref-type="bibr">8</xref>, <xref rid="jocd16707-bib-0013" ref-type="bibr">13</xref>]. This design enables the dermaroller to be tailored to various skin thicknesses and treatment requirements, whether for professional medical aesthetics or daily home care.</p></list-item><list-item id="jocd16707-li-0003"><p>Lower cost&#x02010;effectiveness: Dermaroller is less expensive to maintain than dermapen, which not requires frequent needle changes or the purchase of extra accessories. At the same time, compared to high&#x02010;end technologies like RF microneedling and LED microneedling, dermaroller offers patients a more inexpensive option while still providing effective treatment.</p></list-item></list>
</p></sec><sec id="jocd16707-sec-0013"><label>4.2</label><title>Microneedling Mechanisms of Action in Melasma Treatment</title><p>Although the mechanisms by which microneedling works in melasma treatment remain unclear, it is widely accepted that its main therapeutic benefits come from enhanced transdermal absorption of drugs or bioactive substances and wound healing response stimulation [<xref rid="jocd16707-bib-0014" ref-type="bibr">14</xref>, <xref rid="jocd16707-bib-0015" ref-type="bibr">15</xref>]. The effectiveness of these mechanisms depends on microneedle penetration depth into skin tissue, which in turn, depends on several parameters, including needle length, applied force, and subcutaneous fat levels in the targeted region. It is widely believed that needle tips pierce at a depth of 50%&#x02013;70% of their total length [<xref rid="jocd16707-bib-0016" ref-type="bibr">16</xref>].</p><p>Like a brick wall, intact skin stratum corneum acts as a protective barrier and is critical for maintaining vital physiological processes like reducing water and electrolyte loss, resisting mechanical stress, and exerting anti&#x02010;inflammatory effects [<xref rid="jocd16707-bib-0017" ref-type="bibr">17</xref>]. Being hydrophobic, it naturally restricts the absorption of most pharmacologic agents and active substances, limiting transdermal absorption rates. Consequently, only small medication doses reach target tissues to provide therapeutic effects, which frequently results in unsatisfactory clinical outcomes. Because microneedles with a length of &#x02264;&#x02009;1&#x02009;mm penetrate and temporarily break down the epidermal barrier, they increase the transdermal absorption of medicines and bioactive chemicals [<xref rid="jocd16707-bib-0018" ref-type="bibr">18</xref>]. Although they may also affect the epidermis&#x02013;dermis junction, they cause less bleeding because the superficial dermal layer is only partially affected. This mechanism may boost basal cell activity, rejuvenate aging keratinocytes, minimize stratum corneum accumulation, and aid melanosome evacuation. By piercing the epidermis and reaching the dermis, microneedles with a length of &#x0003e;&#x02009;1&#x02009;mm can trigger a sequence of post&#x02010;traumatic healing processes, which stimulates the release of various factors, including platelets, transforming growth factor &#x003b1; and &#x003b2;, fibroblast growth factor, interleukin 1, and tumor necrosis factor [<xref rid="jocd16707-bib-0018" ref-type="bibr">18</xref>, <xref rid="jocd16707-bib-0019" ref-type="bibr">19</xref>, <xref rid="jocd16707-bib-0020" ref-type="bibr">20</xref>]. These factors promote neovascularization, nutrient and oxygen supply for cellular metabolism, cell migration and proliferation, and collagen and elastin formation. Fibroblast migration and proliferation stimulate extracellular matrix synthesis, including the production of mucopolysaccharides and the expression of collagen and elastin, driving skin tissue remodeling. Furthermore, microneedling can reduce scar formation by increasing transforming growth factor &#x003b2;3 expression, which is critical for enhanced skin pigmentation and overall skin health maintenance [<xref rid="jocd16707-bib-0021" ref-type="bibr">21</xref>].</p><p>In a thorough review of 64 clinical studies, we discovered that researchers preferred using 1.5&#x02009;mm microneedles for melasma treatment and that patients' symptoms improved significantly within 8&#x02013;12&#x02009;weeks. This phenomenon could be attributed to the fact that 1.5&#x02009;mm microneedles can precisely enter the skin to the correct depth, efficiently triggering the dermal repair mechanism without causing excessive skin damage, which is critical for best therapy results.</p></sec><sec id="jocd16707-sec-0014"><label>4.3</label><title>Microneedle Therapy in Melasma</title><sec id="jocd16707-sec-0015"><label>4.3.1</label><title>Single Microneedle Treatment</title><p>In melasma treatment, microneedle therapy has several advantages, especially in skin tissue structure modification, melanin deposition reduction, and boosting melanin particle elimination, which can significantly improve melasma symptoms and increase the quality of life [<xref rid="jocd16707-bib-0022" ref-type="bibr">22</xref>, <xref rid="jocd16707-bib-0023" ref-type="bibr">23</xref>]. Cassiano et&#x000a0;al. [<xref rid="jocd16707-bib-0022" ref-type="bibr">22</xref>] administered microneedle therapy to 20 female patients with melasma and through histopathological examination before and after treatment, found that microneedle treatment markedly reduced melanin density, thickened the epidermis, and reduced basement membrane damage, highlighting its efficacy in melasma treatment.</p><p>However, microneedle therapy is invasive, which may harm skin barrier function, increasing the risk of infection and inflammation [<xref rid="jocd16707-bib-0024" ref-type="bibr">24</xref>]. To address this challenge, Wu et&#x000a0;al. [<xref rid="jocd16707-bib-0025" ref-type="bibr">25</xref>] treated nine patients with melasma using a microneedle fractional radiofrequency system and found that after treatment, patient face transdermal water loss (TEWL) increased temporarily before returning to baseline levels after a week. This finding implies that in the early stages, the microneedle fractional radiofrequency system may impair epidermal barrier function, causing water loss and increased TEWL. However, the return of TEWL values to baseline levels after a week with subsiding cell swelling and epidermal function recovery indicates that skin sensitivity was not altered in the long run. Therefore, although microneedle therapy can damage the epidermal barrier in a short period, it does not easily cause infection.</p><p>Therapeutic impact maintenance and limiting recurrence is critical for melasma treatment and traditional therapeutic methods do not address this issue effectively. However, new research findings indicate that dermal regeneration can be enhanced using targeted therapies, such as radiofrequency, pulsed dye lasers, and pulsed solid light, maintaining therapeutic impact for longer [<xref rid="jocd16707-bib-0026" ref-type="bibr">26</xref>, <xref rid="jocd16707-bib-0027" ref-type="bibr">27</xref>, <xref rid="jocd16707-bib-0028" ref-type="bibr">28</xref>]. For example, Han et&#x000a0;al. [<xref rid="jocd16707-bib-0029" ref-type="bibr">29</xref>] treated 11 female patients with melasma for 2&#x02009;months using a routine treatment that included oral tranexamic acid and a topical triple cream followed by microneedle radiofrequency for maintenance and found that even after conventional therapy discontinuation, the radiofrequency study arm remained better at 6&#x02009;months, whereas in the untreated arm, 63.6% of the participants returned to baseline levels. This indicates that radiofrequency can provide long&#x02010;term therapeutic effects while lowering recurrence likelihood. Furthermore, using radiofrequency therapy on two patients with melasma, Markowitz et&#x000a0;al. [<xref rid="jocd16707-bib-0030" ref-type="bibr">30</xref>] found that skin blood vessel density was markedly reduced following treatment, probably because of radiofrequency use with the Profondmartrix System, which can target three tissue layers in a single operation and effectively releases heat, destroying vascular tissue and minimizing the epidermal cell damage caused by multiple insertions and pulse stacking.</p><p>Finally, microneedle monotherapy is effective in melasma treatment and can be used as maintenance therapy for other treatment modalities (See Table&#x000a0;<xref rid="jocd16707-tbl-0001" ref-type="table">1</xref> for details). Future studies should improve patient satisfaction and outcomes by optimizing treatment schedules.</p></sec><sec id="jocd16707-sec-0016"><label>4.3.2</label><title>Microneedle Drug Delivery</title><p>Melasma is a complex pigmentary disorder influenced by melanosome synthesis, transportation, and metabolism, UV damage, basement membrane disruption, inflammatory responses, improper lipid metabolism, and other factors [<xref rid="jocd16707-bib-0031" ref-type="bibr">31</xref>, <xref rid="jocd16707-bib-0032" ref-type="bibr">32</xref>]. Considering the complexity of melasma development, microneedles alone might not fully meet melasma therapeutic requirements and for maximum therapeutic benefit, it should be combined with additional functional components or medications, these can be used alone or in combination.</p><p>Various medications and active compounds have demonstrated therapeutic effectiveness in treating melasma through their distinct mechanisms. Numerous studies have investigated the combination of microneedle therapy with hydroquinone (HQ), tranexamic acid (TA), vitamin C, ascorbic acid (AA), and platelet&#x02010;rich plasma (PRP), showing notable success with this approach. However, the interaction of microneedle therapy with other treatment agents has not been extensively studied. This gap has piqued our interest, as utilizing microneedles alongside multiple components could present new methods to enhance treatment effectiveness. After thoroughly reviewing 64 clinical studies, as detailed in Table&#x000a0;<xref rid="jocd16707-tbl-0002" ref-type="table">2</xref>, we identified the primary categories of ingredients currently being used in conjunction with microneedling, which include: HQ; nonhydroquinone drugs or ingredients (TA, retinoic acid [ATRA] [<xref rid="jocd16707-bib-0033" ref-type="bibr">33</xref>, <xref rid="jocd16707-bib-0034" ref-type="bibr">34</xref>], methimazole [MMI] [<xref rid="jocd16707-bib-0035" ref-type="bibr">35</xref>], glutathione [<xref rid="jocd16707-bib-0036" ref-type="bibr">36</xref>]); cosmeceuticals and botanicals (AA, glabridin [<xref rid="jocd16707-bib-0037" ref-type="bibr">37</xref>], rucinol [4&#x02010;n&#x02010;butylresorcinol] [<xref rid="jocd16707-bib-0038" ref-type="bibr">38</xref>]);biological therapy (PRP, stem cell exosomes, polynucleotide [PN], hyaluronic acid [HA]).</p><table-wrap position="float" id="jocd16707-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Microneedle drug delivery.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Reference</th><th align="center" valign="bottom" rowspan="1" colspan="1">Microneedle type</th><th align="center" valign="bottom" rowspan="1" colspan="1">Number of subjects</th><th align="center" valign="bottom" rowspan="1" colspan="1">No of sessions (interval)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Treatments</th><th align="center" valign="bottom" rowspan="1" colspan="1">Results</th><th align="center" valign="bottom" rowspan="1" colspan="1">Side effect</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Lima [<xref rid="jocd16707-bib-0039" ref-type="bibr">39</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dr. Roller, 1.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>18 females</p>
<p>Four males</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">2 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;triple decolorizing formula (0.05% ATRA&#x02009;+ 4% HQ&#x02009;+&#x02009;1% FLU)</td><td align="center" valign="top" rowspan="1" colspan="1">MN can treat stubborn melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Erythema and discrete punctuated bleeding</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lima et&#x000a0;al. [<xref rid="jocd16707-bib-0040" ref-type="bibr">40</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dr. Roller, 1.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">Six females</td><td align="center" valign="top" rowspan="1" colspan="1">2 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;triple decolorizing formula</td><td align="center" valign="top" rowspan="1" colspan="1">All patients showed improvement in melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ram&#x000ed;rez&#x02010; Oliveros et&#x000a0;al. [<xref rid="jocd16707-bib-0041" ref-type="bibr">41</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned, 1.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">One female</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;4% HQ sterile serum drug&#x02009;+ Kligman's formula</td><td align="center" valign="top" rowspan="1" colspan="1">Significant improvements were observed in the clinical outcomes and quality of life</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bosamiya and Jain [<xref rid="jocd16707-bib-0042" ref-type="bibr">42</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermaroller, 1.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>32 females</p>
<p>Eight males</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">3 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: MN&#x02009;+&#x02009;depigmentating cream; Group II: Depigmentating cream (0.05% ATRA +&#x02009;2% HQ&#x02009;+&#x02009;0.01% FLU)</td><td align="center" valign="top" rowspan="1" colspan="1">MN provides faster results than topical creams alone</td><td align="center" valign="top" rowspan="1" colspan="1">Mild discomfort and edema: group I, lasting for 2&#x02009;~&#x02009;3&#x02009;days</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Budamakuntla et&#x000a0;al. [<xref rid="jocd16707-bib-0043" ref-type="bibr">43</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermaroller, 1.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>54 females</p>
<p>Six males</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">3 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: MI&#x02009;+ 4&#x02009;mg/mL TA; Group II: MN&#x02009;+&#x02009;4&#x02009;mg/mL TA</td><td align="center" valign="top" rowspan="1" colspan="1">MASI was elevated in both groups, 35.72% and 44.41%, respectively</td><td align="center" valign="top" rowspan="1" colspan="1">Mild erythema, tolerable pain</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Xu et&#x000a0;al. [<xref rid="jocd16707-bib-0044" ref-type="bibr">44</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned, 0.25&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">28 females</td><td align="center" valign="top" rowspan="1" colspan="1">12 (1&#x02009;week)</td><td align="center" valign="top" rowspan="1" colspan="1">Patients received functional microarray of MN&#x02009;+&#x02009;0.5% TA on one side of their face and 0.5% TA on the other</td><td align="center" valign="top" rowspan="1" colspan="1">This device improves the effectiveness of TA in treating melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Dermatographism: 1 patient</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Saraiva et&#x000a0;al. [<xref rid="jocd16707-bib-0045" ref-type="bibr">45</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Eletroderme,</p>
<p>2&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">15 females</td><td align="center" valign="top" rowspan="1" colspan="1">8 (15&#x02009;days)</td><td align="center" valign="top" rowspan="1" colspan="1">4&#x02009;mg/mL TA&#x02009;+ Eletroderme (without RF)</td><td align="center" valign="top" rowspan="1" colspan="1">MASI significantly reduced from 21.33% to 11.19%</td><td align="center" valign="top" rowspan="1" colspan="1">Pain tolerance</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Saleh et&#x000a0;al. [<xref rid="jocd16707-bib-0046" ref-type="bibr">46</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermapen, 1.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">42 females</td><td align="center" valign="top" rowspan="1" colspan="1">4 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: MN&#x02009;+&#x02009;10% TA; Group II: MN</td><td align="center" valign="top" rowspan="1" colspan="1">TA&#x02009;+&#x02009;MN is superior to MN alone</td><td align="center" valign="top" rowspan="1" colspan="1">Mild erythema, burning sensation, discomfort tolerated in most patients</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wali and Parwani [<xref rid="jocd16707-bib-0047" ref-type="bibr">47</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermaroller, 2.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>12 females</p>
<p>Eight male</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">3 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: Oral TA&#x02009;+&#x02009;topical triple cream; Group II: MN&#x02009;+&#x02009;4&#x02009;mg/mL TA</td><td align="center" valign="top" rowspan="1" colspan="1">Triple cream is safe and effective, MN or TA can assist in its treatment</td><td align="center" valign="top" rowspan="1" colspan="1">HP: 40.0% (I)&#x02009;+&#x02009;30% (II)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kaur et&#x000a0;al. [<xref rid="jocd16707-bib-0048" ref-type="bibr">48</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermaroller, 1&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>32 females</p>
<p>Eight males</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">4 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Patients received MN&#x02009;+&#x02009;0.5% TA on one side of the face and MN&#x02009;+&#x02009;distilled water on the other side of the face</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;TA and MN alone are effective in treating melasma</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>HP: 5% patients;</p>
<p>Dryness: 55% patients</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cassiano et&#x000a0;al. [<xref rid="jocd16707-bib-0049" ref-type="bibr">49</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Not mentioned,</p>
<p>1.5&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">64 females</td><td align="center" valign="top" rowspan="1" colspan="1">2 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Group I: MN&#x02009;+&#x02009;Oral placebo; Group II: Oral TA</p>
<p>Group III: MN&#x02009;+ Oral TA; Group IV: Oral placebo</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">TA and MN in different pathways that lead to improvements in melasma</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Oral TA: 3% persistent headache</p>
<p>MN: 9.3% herpes simplex</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Shamsi Meymandi et&#x000a0;al. [<xref rid="jocd16707-bib-0050" ref-type="bibr">50</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dr. Roller,</p>
<p>1.5&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">60 females</td><td align="center" valign="top" rowspan="1" colspan="1">4 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: MN&#x02009;+&#x02009;4% TA; Group II: Topical 4% HQ</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;TA did not differ from 4% HQ in the treatment of melasma.</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;TA had more erythema but less HP than HQ.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ebrahim et&#x000a0;al. [<xref rid="jocd16707-bib-0051" ref-type="bibr">51</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermapen,</p>
<p>1.5&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">56 females</td><td align="center" valign="top" rowspan="1" colspan="1">6 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Right side: MI&#x02009;+&#x02009;4&#x02009;mg/mL TA; Left side: MN&#x02009;+&#x02009;4&#x02009;mg/mL TA</td><td align="center" valign="top" rowspan="1" colspan="1">MI&#x02009;+&#x02009;TA and MN+ TA could be safe and effective in melasma treatment.</td><td align="center" valign="top" rowspan="1" colspan="1">Mild erythema, edema, pain, mild irritation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Farag, AbdElMaksoud and Ismail [<xref rid="jocd16707-bib-0052" ref-type="bibr">52</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermaroller,</p>
<p>1&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">15 females</td><td align="center" valign="top" rowspan="1" colspan="1">8 (1&#x02009;week)</td><td align="center" valign="top" rowspan="1" colspan="1">Right side: MN&#x02009;+&#x02009;mesolighten (3% KA +&#x02009;0.01% TA +&#x02009;4% Azo +&#x02009;1&#x02009;g LAA&#x02009;+&#x02009;water for injection); Left side: MN +&#x02009;4&#x02009;mg/mL TA</td><td align="center" valign="top" rowspan="1" colspan="1">MN+ TA for melasma superior to MN&#x02009;+&#x02009;mesolightening</td><td align="center" valign="top" rowspan="1" colspan="1">Pain, HP, Persistent erythema, Allergy to anesthesia</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Xing et&#x000a0;al. [<xref rid="jocd16707-bib-0053" ref-type="bibr">53</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermapen,</p>
<p>1&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">60 (not mentioned)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (1&#x02009;week)</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Group I: 1.8% liposomal TA; Group II: MN&#x02009;+&#x02009;5% TA solution</p>
<p>Group III: 2% HQ</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Better treatment outcomes in Group III compared to Group I and III</td><td align="center" valign="top" rowspan="1" colspan="1">Erythema aggravation and HP in Group III</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hassan et&#x000a0;al. [<xref rid="jocd16707-bib-0054" ref-type="bibr">54</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermapen,</p>
<p>0.25&#x02013;2&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>57 females</p>
<p>9 males</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">3 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;4&#x02009;mg/mL TA</td><td align="center" valign="top" rowspan="1" colspan="1">Microneedling combined with TA is highly effective in most patients</td><td align="center" valign="top" rowspan="1" colspan="1">Mild discomfort, burning sensation and erythema</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Zaky et&#x000a0;al. [<xref rid="jocd16707-bib-0055" ref-type="bibr">55</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermapen,</p>
<p>1.5&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">50 females</td><td align="center" valign="top" rowspan="1" colspan="1">4 (1&#x02009;week)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: MN&#x02009;+&#x02009;4% TA; Group II: 4% HQ</td><td align="center" valign="top" rowspan="1" colspan="1">4% HQ and MN+ TA are both effective and safe in melasma</td><td align="center" valign="top" rowspan="1" colspan="1">HP: 4% (I),12% (II)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kuster Kaminski Arida et&#x000a0;al. [<xref rid="jocd16707-bib-0056" ref-type="bibr">56</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermaroller,</p>
<p>1.5&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">20 females</td><td align="center" valign="top" rowspan="1" colspan="1">3 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Patients received MN&#x02009;+ 50&#x02009;mg/mL TA on one side of their face, MN&#x02009;+ 0.9% saline on the other</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;TA provided no additional benefit in melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Susmitha et&#x000a0;al. [<xref rid="jocd16707-bib-0057" ref-type="bibr">57</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermaroller,</p>
<p>1.5&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>43 females</p>
<p>2 males</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">12 (1&#x02009;week)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: modified kligman formula (2% HQ&#x02009;+&#x02009;0.025% ARTA +&#x02009;0.1% MOM); Group II: MN +4&#x02009;mg/mL TA; Group III: ID +4&#x02013;8&#x02009;mg/mL TA</td><td align="center" valign="top" rowspan="1" colspan="1">Both have comparable efficacy and can be used as primary or maintenance therapy</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cassiano et&#x000a0;al. [<xref rid="jocd16707-bib-0059" ref-type="bibr">59</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dr. Roller,</p>
<p>1.5&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">64 females</td><td align="center" valign="top" rowspan="1" colspan="1">8 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: Oral placebo, Group II: MN&#x02009;+&#x02009;Oral placebo, Group III: Oral TA, Group IV: MN&#x02009;+&#x02009;Oral TA&#x02009;+&#x02009;Triple combination cream nightly</td><td align="center" valign="top" rowspan="1" colspan="1">These treatments improve epidermal and dermal tissue</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Batra et&#x000a0;al. [<xref rid="jocd16707-bib-0058" ref-type="bibr">58</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermaroller, 1&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>31 females</p>
<p>9 males</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">6 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: Oral TA; Group II: MN&#x02009;+&#x02009;4&#x02009;mg/mL TA</td><td align="center" valign="top" rowspan="1" colspan="1">Oral and transdermal TA are equally effective</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Epigastric discomfort: 10% group I</p>
<p>Pain: 35% group II</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Poostiyan et&#x000a0;al. [<xref rid="jocd16707-bib-0060" ref-type="bibr">60</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dr. Roller,</p>
<p>1.5&#x02013;2&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">27 females</td><td align="center" valign="top" rowspan="1" colspan="1">3 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: Right side: MN&#x02009;+ 100&#x02009;mg/mL TA, Left side: MI&#x02009;+&#x02009;TA; Group II: Right side: MI&#x02009;+ 100&#x02009;mg/mL TA, Left side: MN&#x02009;+ TA</td><td align="center" valign="top" rowspan="1" colspan="1">Comparable results of MI+ TA and MN+ TA in the treatment of facial melasma</td><td align="center" valign="top" rowspan="1" colspan="1">MI showed higher erythema, desquamation, and edema than MN, and PIH was only discovered in MI</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yu et&#x000a0;al. [<xref rid="jocd16707-bib-0061" ref-type="bibr">61</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Polylactic acid MN, 0.4&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>11 females</p>
<p>1 male</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Twice daily for 8&#x02009;weeks</td><td align="center" valign="top" rowspan="1" colspan="1">Patient received polylactic acid MN&#x02009;+ 2.9% TA serum on one side of the face and the other side received 2.9% TA serum</td><td align="center" valign="top" rowspan="1" colspan="1">Improvement of melasma with PLA MN&#x02009;+&#x02009;TA serum is superior to that with TA serum only</td><td align="center" valign="top" rowspan="1" colspan="1">Flaking: 8.3%, improves with increased moisturization</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Zheng et&#x000a0;al. [<xref rid="jocd16707-bib-0062" ref-type="bibr">62</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dr. Roller,0.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">7 females</td><td align="center" valign="top" rowspan="1" colspan="1">3 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+ 5% TA</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;TA improves melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kusumawardani et&#x000a0;al. [<xref rid="jocd16707-bib-0033" ref-type="bibr">33</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">0.5&#x02013;1&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">3 females</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td><td align="center" valign="top" rowspan="1" colspan="1">Liposomal serum containing combination of azelaic acid, 4&#x02010;n&#x02010;butylresorcinol and retinol&#x02009;+&#x02009;microneedling</td><td align="center" valign="top" rowspan="1" colspan="1">MASI, MSS and Melas&#x02010;QoL improved in all patients with the scores of 33.3%&#x02013;85%</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bergmann et&#x000a0;al. [<xref rid="jocd16707-bib-0034" ref-type="bibr">34</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dr. Roller,</p>
<p>1&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">42 females</td><td align="center" valign="top" rowspan="1" colspan="1">4 (15&#x02009;days)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: MN&#x02009;+&#x02009;5% ATRA; Group II: 5% ARTA stripping solution</td><td align="center" valign="top" rowspan="1" colspan="1">Both improved melasma, but MN was ineffective against non&#x02010;enzymatic defenses</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Farag et&#x000a0;al. [<xref rid="jocd16707-bib-0035" ref-type="bibr">35</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermapen,</p>
<p>0.25&#x02009;~&#x02009;0.5&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">30 females</td><td align="center" valign="top" rowspan="1" colspan="1">12 (1&#x02009;week)</td><td align="center" valign="top" rowspan="1" colspan="1">Right side: MN&#x02009;+&#x02009;5% MII; Left side: MN&#x02009;+&#x02009;Placebo</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;MII can significantly improve melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Erythema: 3.3%; HP:3.3%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mohamed, Beshay and Assaf [<xref rid="jocd16707-bib-0036" ref-type="bibr">36</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermapen,</p>
<p>0.5&#x02013;2&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">29 females</td><td align="center" valign="top" rowspan="1" colspan="1">6 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Right side: MN&#x02009;+&#x02009;Glutathione; Left side: MN</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+ glutathione improve melasma better than MN only</td><td align="center" valign="top" rowspan="1" colspan="1">Slight erythema, edema, and dryness</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yan et&#x000a0;al. [<xref rid="jocd16707-bib-0063" ref-type="bibr">63</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dr. Roller,0.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">51 females</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: MN&#x02009;+&#x02009;20&#x02009;mg/mL AA +&#x02009;Human Collagen Repair Dressing + HQ; Group II: Human Collagen Repair Dressing + HQ</td><td align="center" valign="top" rowspan="1" colspan="1">MN in combination with AA, humanoid collagen and HQ improves melasma efficacy</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Transient erythema: 22.2% (I)</p>
<p>Mild itchiness: 12.5% (II)</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ismail et&#x000a0;al. [<xref rid="jocd16707-bib-0064" ref-type="bibr">64</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermaroller,</p>
<p>1.5&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">30 females</td><td align="center" valign="top" rowspan="1" colspan="1">6 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;Pure L&#x02010;Ascorbic acid 20%</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;AA is safe and effective in treating epidermal melasma</td><td align="center" valign="top" rowspan="1" colspan="1">HP: 16.7%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Farshi and Mansouri [<xref rid="jocd16707-bib-0065" ref-type="bibr">65</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermapen,</p>
<p>1.5&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>19 females</p>
<p>1 male</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">4 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Patients received MN&#x02009;+ mesoestetic depigmentatisolution on one side, and Meso +&#x02009;mesoestetic depigmentati solution on the other</td><td align="center" valign="top" rowspan="1" colspan="1">Both MN and Meso decreased the melanin content in epidermal melasma lesions</td><td align="center" valign="top" rowspan="1" colspan="1">Erythema: 20%; Skin dryness: 15% Itching: 20%; Burning sensation: 25%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Menon et&#x000a0;al. [<xref rid="jocd16707-bib-0066" ref-type="bibr">66</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermaroller,</p>
<p>1.5&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">30 females</td><td align="center" valign="top" rowspan="1" colspan="1">4 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Right side: MN&#x02009;+&#x02009;20% AA; Left side: MN&#x02009;+&#x02009;10% TA</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;TA improves melasma better than MN&#x02009;+&#x02009;AA</td><td align="center" valign="top" rowspan="1" colspan="1">Itching and burning sensation: 33.3%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tahoun Mostafa and Amer [<xref rid="jocd16707-bib-0067" ref-type="bibr">67</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermapen,</p>
<p>1.5&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">30 females</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Right side: MN&#x02009;+&#x02009;100&#x02009;mg/mL TA; Left side: MN&#x02009;+&#x02009;20% AA</td><td align="center" valign="top" rowspan="1" colspan="1">Both improve melasma, MN&#x02009;+&#x02009;TA is better for vascular and epidermal pigmentation</td><td align="center" valign="top" rowspan="1" colspan="1">Itching, Erythema, HP</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">El et&#x000a0;al. [<xref rid="jocd16707-bib-0068" ref-type="bibr">68</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermapen,1.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">20 females</td><td align="center" valign="top" rowspan="1" colspan="1">6 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Right side: MN&#x02009;+&#x02009;100&#x02009;mg/mL TA; Left side: MN&#x02009;+&#x02009;30% AA</td><td align="center" valign="top" rowspan="1" colspan="1">Both can improve melasma, TA works better on blood vessels</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Raza et&#x000a0;al. [<xref rid="jocd16707-bib-0069" ref-type="bibr">69</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermapen,0.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>19 females</p>
<p>11 males</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">3 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Right side: MN&#x02009;+&#x02009;100&#x02009;mg/mL TA; Left side: MN&#x02009;+&#x02009;20% AA</td><td align="center" valign="top" rowspan="1" colspan="1">Both are safe and effective in treating melasma</td><td align="center" valign="top" rowspan="1" colspan="1">No significant side effects</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gul et&#x000a0;al. [<xref rid="jocd16707-bib-0070" ref-type="bibr">70</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermaroller</td><td align="center" valign="top" rowspan="1" colspan="1">60 females</td><td align="center" valign="top" rowspan="1" colspan="1">6 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+ 20% AA</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;AA is safe and effective in treating melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Pain, transient erythema</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yan et&#x000a0;al. [<xref rid="jocd16707-bib-0037" ref-type="bibr">37</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">DMN,0.23&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">3 patients</td><td align="center" valign="top" rowspan="1" colspan="1">28 (2&#x02009;days)</td><td align="center" valign="top" rowspan="1" colspan="1">DMN patch was placed on the area of pigmentation beneath the right eye</td><td align="center" valign="top" rowspan="1" colspan="1">DMNs were found safe in clinical trials and selectively lightened chloasma and age spots</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fabbrocini et&#x000a0;al. [<xref rid="jocd16707-bib-0038" ref-type="bibr">38</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">CIT 8, 0.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">20 females</td><td align="center" valign="top" rowspan="1" colspan="1">2 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Right side: MN&#x02009;+&#x02009;decolourizing serum; Left side: Decolourizing serum((rucinol and sophora&#x02010;alpha)</td><td align="center" valign="top" rowspan="1" colspan="1">MN+ decolourizing serum is better than depigmenting serum alone</td><td align="center" valign="top" rowspan="1" colspan="1">Mild erythema</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Honfny et&#x000a0;al. [<xref rid="jocd16707-bib-0071" ref-type="bibr">71</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermapen, 2&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">20 females</td><td align="center" valign="top" rowspan="1" colspan="1">3 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Right side: MN&#x02009;+&#x02009;PRP; Left side: Meso + PRP</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;PRP was increased the expression of TGF&#x02010;&#x003b2; protein</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Honfny et&#x000a0;al. [<xref rid="jocd16707-bib-0072" ref-type="bibr">72</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermapen,2&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>19 females</p>
<p>4 males</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">3 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Right side: MN&#x02009;+ PRP; Left side: Meso + PRP</td><td align="center" valign="top" rowspan="1" colspan="1">Both improve melasma, but patient satisfaction is higher with MN&#x02009;+&#x02009;PRP</td><td align="center" valign="top" rowspan="1" colspan="1">Pain, erythema, and edema</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Boparai, Bhale and Brar [<xref rid="jocd16707-bib-0073" ref-type="bibr">73</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermaroller,</p>
<p>1.5&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>18 females</p>
<p>12 males</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">3 (3&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;PRP</td><td align="center" valign="top" rowspan="1" colspan="1">PRP is safe and effective in treating melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Mild erythema: 80% patients</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gharib, Mostafa and Ghonemy [<xref rid="jocd16707-bib-0074" ref-type="bibr">74</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned,1.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">26 females</td><td align="center" valign="top" rowspan="1" colspan="1">Four patients</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: MN&#x02009;+&#x02009;4&#x02009;mg/mL TA; Group II: MN&#x02009;+&#x02009;PRP</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;PRP improves melasma better than MN&#x02009;+&#x02009;TA</td><td align="center" valign="top" rowspan="1" colspan="1">TA exhibited higher erythema than PRP but less pain and HP</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Panda et&#x000a0;al. [<xref rid="jocd16707-bib-0075" ref-type="bibr">75</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermaroller,1&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>31 females</p>
<p>20 males</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">3 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: MN&#x02009;+&#x02009;PRP; Group II: MN</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;PRP is safe and effective in treating melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Mild erythema, edema, and pain</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tekam and Belgaumkar [<xref rid="jocd16707-bib-0076" ref-type="bibr">76</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermapen,</p>
<p>0.5&#x02009;~&#x02009;2&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>17 females</p>
<p>13 males</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">4 (3&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Right side: MN&#x02009;+&#x02009;PRP&#x02009;+&#x02009;4% HQ; Left side: MN&#x02009;+&#x02009;Saline+4% HQ</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;PRP&#x02009;+&#x02009;HQ is superior to MN&#x02009;+&#x02009;HQ for melasma improvement</td><td align="center" valign="top" rowspan="1" colspan="1">Mild erythema</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ragaie et&#x000a0;al. [<xref rid="jocd16707-bib-0069" ref-type="bibr">69</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermapen,1&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">10 females</td><td align="center" valign="top" rowspan="1" colspan="1">6 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Right side: MN&#x02009;+&#x02009;20% AA; Left side: MN&#x02009;+ PRP</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;AA is better than MN&#x02009;+&#x02009;PRP in improving mixed melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Transient erythema and burning sensation: 30%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wang et&#x000a0;al. [<xref rid="jocd16707-bib-0077" ref-type="bibr">77</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermaroller,1&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">60 females</td><td align="center" valign="top" rowspan="1" colspan="1">4 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Group I:NAFL +&#x02009;normal saline; Group II: MN&#x02009;+&#x02009;hUCMSC&#x02010;Exos</p>
<p>Group III: NAFL + hUCMSC&#x02010;Exos; Group IV: PBASM&#x02009;+ hUCMSC&#x02010;Exos</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">hUCMSC&#x02010;Exos is safe and effective. MN, NAFL, and PBASM have similar pro&#x02010;osmotic effects</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Erythema: 40% (I), 13.3% (II), 13.3%</p>
<p>(III); Pain and irritation: 6.7% (II)</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gulfan et&#x000a0;al. [<xref rid="jocd16707-bib-0078" ref-type="bibr">78</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">RF,0.8&#x02009;mm, 1.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">30 females</td><td align="center" valign="top" rowspan="1" colspan="1">3 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Patient received RF&#x02009;+&#x02009;PN on one side of the face and the other side received RF</td><td align="center" valign="top" rowspan="1" colspan="1">Both are safe and effective in improving melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Mild erythema and pain, relapsing</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Avcil et&#x000a0;al. [<xref rid="jocd16707-bib-0079" ref-type="bibr">79</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">HA&#x02010;MA, 0.35&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">10 patients</td><td align="center" valign="top" rowspan="1" colspan="1">12&#x02009;weeks (1 time per day)</td><td align="center" valign="top" rowspan="1" colspan="1">HA&#x02010;MA in melasma areas</td><td align="center" valign="top" rowspan="1" colspan="1">HA&#x02010;MA improves melasma and enhances skin brightness</td><td align="center" valign="top" rowspan="1" colspan="1">No associated dermatology&#x02010;related skin changes were caused</td></tr></tbody></table><table-wrap-foot id="jocd16707-ntgp-0003"><fn id="jocd16707-note-0003"><p>Abbreviations: AA, vitamin C; ARTA, retinoic acid; DMN, dissolving microneedles; FLU, fluocinolone acetonide; FMN, functional microarray of microneedles; HA, hyaluronic acid; HA&#x02010;MA, hyaluronic acid&#x02010;based microneedles; HP, hyperpigmentation; HQ, hydroquinone; hUCMSC&#x02010;Exos, human umbilical cord mesenchymal stem cell&#x02010;derived exosomes; ID, intradermal injection; Meso, mesotherapy; MI, microinjection; MMI, methylimidazole; MN, microneedling; NAFL, nonablative fractional laser; PBASM, Peninsula Blue Aurora Shumin Master; PN, polynucleotide; PRP, platelet&#x02010;rich plasma (PRP); TA, tranexamic acid.</p></fn></table-wrap-foot></table-wrap><p>HQ has long been considered the gold standard for treating melasma, with doses ranging from 2% to 4% [<xref rid="jocd16707-bib-0039" ref-type="bibr">39</xref>, <xref rid="jocd16707-bib-0040" ref-type="bibr">40</xref>, <xref rid="jocd16707-bib-0041" ref-type="bibr">41</xref>, <xref rid="jocd16707-bib-0042" ref-type="bibr">42</xref>]. It is commonly mixed with retinoids and steroids to create the well&#x02010;known triple cream. Bosamiya et&#x000a0;al. [<xref rid="jocd16707-bib-0042" ref-type="bibr">42</xref>] found that when compared with triple cream alone, combining microneedles with triple cream resulted in a higher Melasma Area and Severity Index (MASI). This novel combined therapy not only builds on hydroquinone's documented efficacy but also uses microneedling's increased permeability, providing patients with a more effective and less irritating therapeutic choice.</p><p>TA is emerging as a new star in the treatment of melasma due to its various modes of action and excellent safety record [<xref rid="jocd16707-bib-0043" ref-type="bibr">43</xref>, <xref rid="jocd16707-bib-0044" ref-type="bibr">44</xref>, <xref rid="jocd16707-bib-0045" ref-type="bibr">45</xref>, <xref rid="jocd16707-bib-0046" ref-type="bibr">46</xref>, <xref rid="jocd16707-bib-0047" ref-type="bibr">47</xref>, <xref rid="jocd16707-bib-0048" ref-type="bibr">48</xref>, <xref rid="jocd16707-bib-0049" ref-type="bibr">49</xref>, <xref rid="jocd16707-bib-0050" ref-type="bibr">50</xref>, <xref rid="jocd16707-bib-0051" ref-type="bibr">51</xref>, <xref rid="jocd16707-bib-0052" ref-type="bibr">52</xref>, <xref rid="jocd16707-bib-0053" ref-type="bibr">53</xref>, <xref rid="jocd16707-bib-0054" ref-type="bibr">54</xref>, <xref rid="jocd16707-bib-0055" ref-type="bibr">55</xref>, <xref rid="jocd16707-bib-0056" ref-type="bibr">56</xref>, <xref rid="jocd16707-bib-0057" ref-type="bibr">57</xref>, <xref rid="jocd16707-bib-0058" ref-type="bibr">58</xref>, <xref rid="jocd16707-bib-0059" ref-type="bibr">59</xref>, <xref rid="jocd16707-bib-0060" ref-type="bibr">60</xref>, <xref rid="jocd16707-bib-0061" ref-type="bibr">61</xref>, <xref rid="jocd16707-bib-0062" ref-type="bibr">62</xref>]. In clinical practice, topical TA concentrations range from 0.4% to 10%, with varied therapeutic benefits. Higher doses of TA may theoretically result in greater efficacy due to better tyrosinase inhibition. However, they may also be associated with an increased risk of side effects, as demonstrated by research by Saleh et&#x000a0;al. and Poostiyan et&#x000a0;al. [<xref rid="jocd16707-bib-0046" ref-type="bibr">46</xref>, <xref rid="jocd16707-bib-0060" ref-type="bibr">60</xref>]. It is worth noting that more and more studies are favoring the use of TA concentrations of 4&#x02009;mg/mL (0.4%), which could be because when combined with microneedling, satisfactory therapeutic results can be achieved even with lower TA concentrations, as supported by the study of Budamakuntla et&#x000a0;al. [<xref rid="jocd16707-bib-0043" ref-type="bibr">43</xref>]. Furthermore, complex formulations containing TA have emerged as a new trend in the treatment of melasma due to their combination with other active ingredients such as vitamin C, glutathione, and tretinoin, which not only improve treatment efficacy through synergistic effects but may also reduce the risk of side effects. However, Farag et&#x000a0;al. [<xref rid="jocd16707-bib-0052" ref-type="bibr">52</xref>] found that microneedling combined with a composite formulation of 0.01% TA was no more effective than microneedling treatment with 0.4% TA alone. This discovery challenges our traditional beliefs of combination formulations. It implies that while seeking therapeutic efficacy, we should also prioritize the simplicity and safety of formulations to ensure patients receive both effective and gentle therapies.</p><p>AA has garnered popularity in skincare due to its versatility, with concentrations varying from 3.75% to 30% [<xref rid="jocd16707-bib-0037" ref-type="bibr">37</xref>, <xref rid="jocd16707-bib-0063" ref-type="bibr">63</xref>, <xref rid="jocd16707-bib-0064" ref-type="bibr">64</xref>, <xref rid="jocd16707-bib-0065" ref-type="bibr">65</xref>, <xref rid="jocd16707-bib-0066" ref-type="bibr">66</xref>, <xref rid="jocd16707-bib-0067" ref-type="bibr">67</xref>, <xref rid="jocd16707-bib-0068" ref-type="bibr">68</xref>, <xref rid="jocd16707-bib-0069" ref-type="bibr">69</xref>, <xref rid="jocd16707-bib-0070" ref-type="bibr">70</xref>]. We find that researchers have particularly endorsed the 20% concentration. Ismail ESA et&#x000a0;al. [<xref rid="jocd16707-bib-0064" ref-type="bibr">64</xref>] has demonstrated that the combination of 20% AA with micro needling in melasma treatment significantly enhances skin quality and diminishes the size and color intensity of melasma lesions, affirming the safety and efficacy of this high AA concentration. Menon et&#x000a0;al.'s [<xref rid="jocd16707-bib-0066" ref-type="bibr">66</xref>] research revealed that microneedling with 20% AA or 10% TA was as effective as melasma, yet 20% AA presented fewer side effects, underscoring the superior safety and tolerability of the higher AA concentration. In a groundbreaking development, dissolvable microneedles (DMN), which incorporate many components, including AA, as Yan et&#x000a0;al. [<xref rid="jocd16707-bib-0037" ref-type="bibr">37</xref>] devised, present patients with a straightforward and potent therapeutic alternative. This cutting&#x02010;edge technology enables medications to target the deeper layers of the skin more accurately, thereby augmenting the efficacy of therapy and minimizing potential harm to healthy skin. This treatment paradigm not only deepens our comprehension of AA's role in microneedling but also expands the array of treatment options available to individuals afflicted with melasma.</p><p>The emergence of biotherapeutics, such as PRP, stem cell therapies, PN, and HA, has changed the treatment landscape for melasma [<xref rid="jocd16707-bib-0071" ref-type="bibr">71</xref>, <xref rid="jocd16707-bib-0072" ref-type="bibr">72</xref>, <xref rid="jocd16707-bib-0073" ref-type="bibr">73</xref>, <xref rid="jocd16707-bib-0074" ref-type="bibr">74</xref>, <xref rid="jocd16707-bib-0075" ref-type="bibr">75</xref>, <xref rid="jocd16707-bib-0076" ref-type="bibr">76</xref>, <xref rid="jocd16707-bib-0077" ref-type="bibr">77</xref>, <xref rid="jocd16707-bib-0078" ref-type="bibr">78</xref>, <xref rid="jocd16707-bib-0079" ref-type="bibr">79</xref>]. PRP therapy has proven to be a game&#x02010;changer, effectively reducing hyperpigmentation and enhancing patients' quality of life. Honfny ERM et&#x000a0;al. [<xref rid="jocd16707-bib-0071" ref-type="bibr">71</xref>] have discovered that the synergy of microneedling with PRP therapy significantly increases TGF&#x02010;&#x003b2; protein expression, thereby markedly improving melasma symptoms. This breakthrough sets the stage for further exploration, where subsequent studies have shown that microneedle injections are just as effective as traditional intradermal PRP injections, highlighting that the delivery method does not dictate the success of the treatment [<xref rid="jocd16707-bib-0072" ref-type="bibr">72</xref>]. Crucially, the integration of microneedles with PRP has been shown to significantly minimize patient discomfort, pain, bleeding, and infection risk, as opposed to conventional injections. This advancement has bolstered the therapy's safety and increased patient acceptance. Panda et&#x000a0;al. [<xref rid="jocd16707-bib-0075" ref-type="bibr">75</xref>] have added to this body of evidence, noting a substantial rise in patient satisfaction and treatment efficacy when microneedles are used with PRP. These findings collectively endorse the efficacy of the combined treatment approach, painting a promising future for this method in melasma treatment. In addition to PRP, the union of microneedling with stem cell therapy has unveiled impressive therapeutic outcomes. Wang et&#x000a0;al. [<xref rid="jocd16707-bib-0077" ref-type="bibr">77</xref>] demonstrated that the marriage of human umbilical cord mesenchymal stem cell exosomes (hUCMSC&#x02010;Exos) and microneedling is both safe and efficacious in combating melasma. Moreover, the study underscored that microneedling, when combined with nonablative fractional laser (NAFL) and plasma devices (PBASM), can significantly enhance the transdermal penetration of exosomes, unveiling a cutting&#x02010;edge strategy for melasma therapy. These discoveries have introduced innovative concepts for melasma treatment and underscore the pivotal role of biotherapeutics in enhancing treatment efficacy and patient comfort.</p><p>In conclusion, the combination of microneedling and beneficial compounds or medications offers a more comprehensive and effective therapeutic regimen for numerous melasma pathologic causes. In the future, studies should investigate the best combination of various agents with microneedling and how to optimize therapeutic efficacy via optimal treatment routines.</p></sec><sec id="jocd16707-sec-0017"><label>4.3.3</label><title>Microneedle Combined Therapy</title><p>Melasma treatment primarily eliminates melanosomes by facilitating their excretion via the inhibition of tyrosinase and associated proteins. Currently, a wide range of technologies, including Q&#x02010;switched lasers, picosecond lasers, and pulsed solid light are used for melasma treatment. However, the use of such technologies alone has limitations, such as the risk of severe responses and melasma recurrence. Therefore, for greater curative efficacy, we recommend combining various technologies targeted at distinct therapeutic targets. Multiple studies have demonstrated the superiority of combination therapy in melasma treatment and although previous studies have mainly focused on photoelectric therapy, there is growing interest in alternate therapeutic modalities (See Table&#x000a0;<xref rid="jocd16707-tbl-0003" ref-type="table">3</xref> for details).</p><table-wrap position="float" id="jocd16707-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Microneedle combined therapy.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Reference</th><th align="center" valign="bottom" rowspan="1" colspan="1">Microneedle Type</th><th align="center" valign="bottom" rowspan="1" colspan="1">Number of subjects</th><th align="center" valign="bottom" rowspan="1" colspan="1">No of sessions (interval)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Results</th><th align="center" valign="bottom" rowspan="1" colspan="1">Side effects</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Ustuner et&#x000a0;al. [<xref rid="jocd16707-bib-0080" ref-type="bibr">80</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermapen,</p>
<p>1.5&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>15 females</p>
<p>One male</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">12 (4&#x02009;week)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: QSNY&#x02009;+&#x02009;MN&#x02009;+&#x02009;AA; Group II: QSNY</td><td align="center" valign="top" rowspan="1" colspan="1">QSNY+MN&#x02009;+&#x02009;AA is safe and effective in treating stubborn melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Transient erythema, HP, irritation</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quan et&#x000a0;al. [<xref rid="jocd16707-bib-0081" ref-type="bibr">81</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermaroller, 0.5&#x02009;mm, 1&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">90 females</td><td align="center" valign="top" rowspan="1" colspan="1">4 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Group I: QSNY + MN&#x02009;+ compound repair of oligosaccharides</p>
<p>Group II: Laser alone</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">QSNY + compound repair of oligosaccharides improves melasma better than QSNY only</td><td align="center" valign="top" rowspan="1" colspan="1">Not mentioned</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Jung et&#x000a0;al. [<xref rid="jocd16707-bib-0082" ref-type="bibr">82</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">RF,1&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>14 females</p>
<p>One male</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Right side: QSNY&#x02009;+&#x02009;RF; Left side: QSNY</td><td align="center" valign="top" rowspan="1" colspan="1">QSNY+RF improves melasma better than QSNY only</td><td align="center" valign="top" rowspan="1" colspan="1">Mild pain, discomfort tolerated by most patients</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kwon et&#x000a0;al. [<xref rid="jocd16707-bib-0083" ref-type="bibr">83</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">FMR,0.5&#x02009;~&#x02009;1&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>19 females</p>
<p>Five males</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">10 (1&#x02009;week)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: QSNY&#x02009;+&#x02009;FMR; Group II: QSNY alone</td><td align="center" valign="top" rowspan="1" colspan="1">QSNY&#x02009;+&#x02009;FRM improves melasma better than QSNY only</td><td align="center" valign="top" rowspan="1" colspan="1">Group I had more mottled HP and rebound HP than Group II</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Karada&#x0011f; and Borlu [<xref rid="jocd16707-bib-0084" ref-type="bibr">84</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermapen, 2&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">15 females</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">QSNY&#x02009;+&#x02009;MN&#x02009;+ biomimetic peptide formulation</td><td align="center" valign="top" rowspan="1" colspan="1">QSNY+RF+ biomimetic peptides are safe and effective in treating melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Mild&#x02010;to&#x02010;moderate erythema</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lee et&#x000a0;al. [<xref rid="jocd16707-bib-0086" ref-type="bibr">86</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">FMR,0.3&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">25 females</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Patients receive QSNY&#x02009;+RF on one side of the face, and QSNY only on the other side</td><td align="center" valign="top" rowspan="1" colspan="1">QSNY+RF improved melanin index and half&#x02010;face MASI better than QCNY</td><td align="center" valign="top" rowspan="1" colspan="1">Tolerable pain, erythema, and crusting</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Debasmita et&#x000a0;al. [<xref rid="jocd16707-bib-0085" ref-type="bibr">85</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermaroller, 1.5&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>42 females</p>
<p>18 males</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">5 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: Laser&#x02009;+&#x02009;3% TA gel; Group II: MN&#x02009;+&#x02009;3% TA gel</td><td align="center" valign="top" rowspan="1" colspan="1">Both have the same efficacy in improving melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Burning sensation, pain, erythema more in Group II than Group I</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mekawy, Sadek and Seddeik Abdel&#x02010;Hameed [<xref rid="jocd16707-bib-0087" ref-type="bibr">87</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermapen,</p>
<p>0.25&#x02009;&#x02013;&#x02009;1&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">30 females</td><td align="center" valign="top" rowspan="1" colspan="1">6 (2&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Patients received MN&#x02009;+&#x02009;TA on one side of their face, and fractional ablative CO2 laser&#x02009;+&#x02009;4&#x02009;mg/mL TA on the other</td><td align="center" valign="top" rowspan="1" colspan="1">Both MN and CO2 laser delivery of TA are safe and effective.</td><td align="center" valign="top" rowspan="1" colspan="1">HP: 10% MN side</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mamdouh et&#x000a0;al. [<xref rid="jocd16707-bib-0088" ref-type="bibr">88</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Dermapen,</p>
<p>0.25&#x02009;&#x02013;&#x02009;1&#x02009;mm</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">30 females</td><td align="center" valign="top" rowspan="1" colspan="1">4 (3&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I: Fractional CO2 laser&#x02009;+&#x02009;5% TA cream; Group II: MN&#x02009;+&#x02009;5% TA&#x02009;+&#x02009;5% TA cream; Group III: 5% TA cream</td><td align="center" valign="top" rowspan="1" colspan="1">TA+ MN or CO2 laser is superior to TA alone in improving melasma.</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Recurrence: III&#x02009;&#x0003e;&#x02009;I&#x02009;&#x0003e;&#x02009;II; HP: I</p>
<p>Dryness and transient irritation: II&#x02009;&#x0003e;&#x02009;I&#x02009;=&#x02009;III</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hofny et&#x000a0;al. [<xref rid="jocd16707-bib-0089" ref-type="bibr">89</xref>]</td><td align="center" valign="top" rowspan="1" colspan="1">Dermapen, 2&#x02009;mm</td><td align="center" valign="top" rowspan="1" colspan="1">40 females</td><td align="center" valign="top" rowspan="1" colspan="1">4 (4&#x02009;weeks)</td><td align="center" valign="top" rowspan="1" colspan="1">Group I:MN&#x02009;+ 25% TCA; Group II: 25% TCA</td><td align="center" valign="top" rowspan="1" colspan="1">MN&#x02009;+&#x02009;TCA is safe and effective in treating melasma</td><td align="center" valign="top" rowspan="1" colspan="1">Burning sensation and enterythema: II&#x02009;&#x0003e;&#x02009;I; Folliculitis: I; HP: II</td></tr></tbody></table><table-wrap-foot id="jocd16707-ntgp-0004"><fn id="jocd16707-note-0004"><p>Abbreviations: FME, fractional microneedling radiofrequency; QSNY, QS&#x02010;Nd:YAG laser; TCA, trichloroacetic acid.</p></fn></table-wrap-foot></table-wrap><p>The combination of microneedle therapy with Qs&#x02010;Nd:YAG laser therapy is often used in melasma phototherapy studies [<xref rid="jocd16707-bib-0080" ref-type="bibr">80</xref>, <xref rid="jocd16707-bib-0081" ref-type="bibr">81</xref>, <xref rid="jocd16707-bib-0082" ref-type="bibr">82</xref>, <xref rid="jocd16707-bib-0083" ref-type="bibr">83</xref>, <xref rid="jocd16707-bib-0084" ref-type="bibr">84</xref>, <xref rid="jocd16707-bib-0085" ref-type="bibr">85</xref>, <xref rid="jocd16707-bib-0086" ref-type="bibr">86</xref>, <xref rid="jocd16707-bib-0087" ref-type="bibr">87</xref>, <xref rid="jocd16707-bib-0088" ref-type="bibr">88</xref>]. For example, Ustuner et&#x000a0;al. [<xref rid="jocd16707-bib-0080" ref-type="bibr">80</xref>] treated 16 female patients with persistent melasma using vitamin C microneedle therapy combined with Qs&#x02010;Nd:YAG laser treatment and found that the combined treatment group exhibited significantly superior MASI score improvement when compared to the group treated with laser alone. This is probably because the Qs&#x02010;Nd:YAG laser generates heat, which promotes dermal blood circulation, thereby boosting microneedle mechanical activity and enhancing vitamin C transdermal absorption. Furthermore, Mekawy et&#x000a0;al. [<xref rid="jocd16707-bib-0087" ref-type="bibr">87</xref>] treated 30 female patients with melasma using six treatments of CO<sub>2</sub> laser and microneedle therapy and observed that the control group (CO<sub>2</sub> laser combined with 4&#x02009;mg/mL tranexamic acid) and the combination group (microneedle therapy combined with 4&#x02009;mg/mL of tranexamic acid) exhibited significantly reduced mMASI scores and that the difference between the two groups was not statistically significant, confirming that drug delivery using CO<sub>2</sub> laser and microneedles is safe and efficacious.</p><p>Microneedle therapy has also exhibited melasma treatment potential when combined with other therapies, such as chemical stripping. In a trial that treated 40 female patients with melasma using 25% trichloroacetic acid and microneedling, Hofny et&#x000a0;al. [<xref rid="jocd16707-bib-0089" ref-type="bibr">89</xref>] observed that in the combined treatment group, the mMASI score was better when compared with the control group treated using 25% trichloroacetic acid alone. This is probably because trichloroacetic acid stripping removed excess melanin, promoting epidermal renewal, while microneedling enhanced trichloroacetic acid transdermal absorption and stimulated dermal hyperplasia. This study confirmed the safety and efficacy of 25% trichloroacetic acid when combined with microneedling.</p><p>Finally, combining microneedle therapy with other techniques offers a new melasma treatment method that can improve therapeutic efficacy while reducing adverse responses through the synergistic effects of several mechanisms. To improve treatment efficacy and patient satisfaction, future studies should investigate the optimal combination of microneedle therapy and other treatments and optimize treatment plans.</p></sec></sec></sec><sec sec-type="conclusions" id="jocd16707-sec-0018"><label>5</label><title>Conclusion</title><p>Microneedling, a skin therapy technique that creates controlled microinjuries, has gained popularity because it can cure various skin problems, including melasma. This comprehensive review examined the role of microneedling in melasma treatment, focusing on its therapeutic advantages and safety. Its advantages include a short recovery time, enhanced percutaneous topical medication absorption, and high tolerability across various skin types. Moreover, during melasma treatment, it exhibits few side effects, with the most prevalent one being transient redness and mild discomfort, which are handled well by patients [<xref rid="jocd16707-bib-0005" ref-type="bibr">5</xref>].</p><p>Unlike traditional melasma therapies, microneedling preserves epidermal integrity promotes basement membrane regeneration, and does not significantly stimulate melanocyte proliferation. Additionally, it reduces the risk of hyperpigmentation, which, because of inflammation, is commonly associated with the healing process [<xref rid="jocd16707-bib-0090" ref-type="bibr">90</xref>]. When combined with other treatment techniques, microneedle therapy has shown promise for reducing melasma incidence relapse and accompanying hyperpigmentation. However, because current clinical studies on melasma treatment using microneedling are hampered by small sample sizes, larger studies are needed to eliminate potential biases, including publication and follow&#x02010;up bias. Furthermore, microneedle combination therapies are limited, and investigating a broader range of combination protocols may be critical for improved therapeutic success. Future research efforts should also prioritize the determination of the optimal needle penetration depth and treatment regimen, which depend on the patient's skin tone. To maximize clinical outcomes for patients with melasma, emphasis should be placed on identifying the ideal needle length [<xref rid="jocd16707-bib-0091" ref-type="bibr">91</xref>]. Taken together, current evidence highlights microneedling as a novel and effective melasma treatment option, with a good safety profile and few side effects. However, further research is needed to better understand its clinical applications and refine treatment regimens.</p></sec><sec id="jocd16707-sec-0021"><title>Author Contributions</title><p>Wenwen Chen contributed to the writing of this paper, while Xingling Jian and Bo Yu were involved in its finalization.</p></sec><sec sec-type="COI-statement" id="jocd16707-sec-0020"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="jocd16707-sec-0019"><title>Acknowledgments</title><p>We thank Shenzhen Public Service Platform of Biomedical Technology for the technical support. We sincerely thank Jieyi Wang for her valuable revisions and suggestions regarding this research manuscript.</p></ack><sec sec-type="data-availability" id="jocd16707-sec-0023"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="jocd16707-bibl-0001"><title>References</title><ref id="jocd16707-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jocd16707-cit-0001">
<string-name>
<given-names>T.</given-names>
<surname>Passeron</surname>
</string-name> and <string-name>
<given-names>M.</given-names>
<surname>Picardo</surname>
</string-name>, &#x0201c;<article-title>Melasma, a Photoaging Disorder</article-title>,&#x0201d; <source>Pigment Cell &#x00026; Melanoma Research</source>
<volume>31</volume>, no. <issue>4</issue> (<year>2018</year>): <fpage>461</fpage>&#x02013;<lpage>465</lpage>.<pub-id pub-id-type="pmid">29285880</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jocd16707-cit-0002">
<string-name>
<given-names>A.</given-names>
<surname>Esp&#x000f3;sito</surname>
</string-name>, <string-name>
<given-names>D. P.</given-names>
<surname>Cassiano</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>da</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Update on Melasma&#x02010;Part I: Pathogenesis</article-title>,&#x0201d; <source>Dermatology and Therapy</source>
<volume>12</volume>, no. <issue>9</issue> (<year>2022</year>): <fpage>1967</fpage>&#x02013;<lpage>1988</lpage>.<pub-id pub-id-type="pmid">35904706</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0003"><label>3</label><mixed-citation publication-type="book" id="jocd16707-cit-0003">
<string-name>
<given-names>G.</given-names>
<surname>Litchman</surname>
</string-name>, <string-name>
<given-names>P. A.</given-names>
<surname>Nair</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Badri</surname>
</string-name>, and <string-name>
<given-names>S. E.</given-names>
<surname>Kelly</surname>
</string-name>, &#x0201c;<part-title>Microneedling</part-title>,&#x0201d; in <source>StatPearls</source> (<publisher-loc>Treasure Island, FL</publisher-loc>: <publisher-name>StatPearls</publisher-name>, <year>2022</year>).</mixed-citation></ref><ref id="jocd16707-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jocd16707-cit-0004">
<string-name>
<given-names>D. S.</given-names>
<surname>Orentreich</surname>
</string-name> and <string-name>
<given-names>N.</given-names>
<surname>Orentreich</surname>
</string-name>, &#x0201c;<article-title>Subcutaneous Incisionless (Subcision) Surgery for the Correction of Depressed Scars and Wrinkles</article-title>,&#x0201d; <source>Dermatologic Surgery</source>
<volume>21</volume>, no. <issue>6</issue> (<year>1995</year>): <fpage>543</fpage>&#x02013;<lpage>549</lpage>.<pub-id pub-id-type="pmid">7773602</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jocd16707-cit-0005">
<string-name>
<given-names>S.</given-names>
<surname>Doddaballapur</surname>
</string-name>, &#x0201c;<article-title>Microneedling With Dermaroller</article-title>,&#x0201d; <source>Journal of Cutaneous and Aesthetic Surgery</source>
<volume>2</volume>, no. <issue>2</issue> (<year>2009</year>): <fpage>110</fpage>&#x02013;<lpage>111</lpage>.<pub-id pub-id-type="pmid">20808602</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jocd16707-cit-0006">
<string-name>
<given-names>A.</given-names>
<surname>Singh</surname>
</string-name> and <string-name>
<given-names>S.</given-names>
<surname>Yadav</surname>
</string-name>, &#x0201c;<article-title>Microneedling: Advances and Widening Horizons</article-title>,&#x0201d; <source>Indian Dermatology Online Journal</source>
<volume>7</volume>, no. <issue>4</issue> (<year>2016</year>): <fpage>244</fpage>&#x02013;<lpage>254</lpage>.<pub-id pub-id-type="pmid">27559496</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jocd16707-cit-0007">
<string-name>
<given-names>K.</given-names>
<surname>Shivaram</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Edwards</surname>
</string-name>, and <string-name>
<given-names>T. F.</given-names>
<surname>Mohammad</surname>
</string-name>, &#x0201c;<article-title>An Update on the Safety of Hydroquinone</article-title>,&#x0201d; <source>Archives of Dermatological Research</source>
<volume>316</volume>, no. <issue>7</issue> (<year>2024</year>): <fpage>378</fpage>.<pub-id pub-id-type="pmid">38850450</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jocd16707-cit-0008">
<string-name>
<given-names>M. T.</given-names>
<surname>McCrudden</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>McAlister</surname>
</string-name>, <string-name>
<given-names>A. J.</given-names>
<surname>Courtenay</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Gonz&#x000e1;lez&#x02010;V&#x000e1;zquez</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Raj</surname>
</string-name>, and <string-name>
<given-names>R.</given-names>
<surname>Donnelly</surname>
</string-name>, &#x0201c;<article-title>Microneedle Applications in Improving Skin Appearance</article-title>,&#x0201d; <source>Experimental Dermatology</source>
<volume>24</volume>, no. <issue>8</issue> (<year>2015</year>): <fpage>561</fpage>&#x02013;<lpage>566</lpage>.<pub-id pub-id-type="pmid">25865925</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jocd16707-cit-0009">
<string-name>
<given-names>S.</given-names>
<surname>Arora</surname>
</string-name> and <string-name>
<given-names>P. B.</given-names>
<surname>Gupta</surname>
</string-name>, &#x0201c;<article-title>Automated Microneedling Device&#x02014;A New Tool in dermatologist's Kit&#x02014;A Review</article-title>,&#x0201d; <source>Journal of Pakistan Association of Dermatologists</source>
<volume>22</volume>, no. <issue>4</issue> (<year>2012</year>): <fpage>354</fpage>&#x02013;<lpage>357</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jocd16707-cit-0010">
<string-name>
<given-names>B. E.</given-names>
<surname>Cohen</surname>
</string-name> and <string-name>
<given-names>N.</given-names>
<surname>Elbuluk</surname>
</string-name>, &#x0201c;<article-title>Microneedling in Skin of Color: A Review of Uses and Efficacy</article-title>,&#x0201d; <source>Journal of the American Academy of Dermatology</source>
<volume>74</volume>, no. <issue>2</issue> (<year>2016</year>): <fpage>348</fpage>&#x02013;<lpage>355</lpage>.<pub-id pub-id-type="pmid">26549251</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jocd16707-cit-0011">
<string-name>
<given-names>B. S.</given-names>
<surname>Chandrashekar</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Sriram</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Mysore</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Bhaskar</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Shetty</surname>
</string-name>, &#x0201c;<article-title>Evaluation of Microneedling Fractional Radiofrequency Device for Treatment of Acne Scars</article-title>,&#x0201d; <source>Journal of Cutaneous and Aesthetic Surgery</source>
<volume>7</volume>, no. <issue>2</issue> (<year>2014</year>): <fpage>93</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">25136209</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jocd16707-cit-0012">
<string-name>
<given-names>S. H.</given-names>
<surname>Bariya</surname>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>Gohel</surname>
</string-name>, <string-name>
<given-names>T. A.</given-names>
<surname>Mehta</surname>
</string-name>, and <string-name>
<given-names>O. P.</given-names>
<surname>Sharma</surname>
</string-name>, &#x0201c;<article-title>Microneedles: An Emerging Transdermal Drug Delivery System</article-title>,&#x0201d; <source>Journal of Pharmacy and Pharmacology</source>
<volume>64</volume>, no. <issue>1</issue> (<year>2012</year>): <fpage>11</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">22150668</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jocd16707-cit-0013">
<string-name>
<given-names>A.</given-names>
<surname>Bahuguna</surname>
</string-name>, &#x0201c;<article-title>Micro Needling&#x02014;Facts and Fictions</article-title>,&#x0201d; <source>Asian Journal of Medical Sciences</source>
<volume>4</volume>, no. <issue>3</issue> (<year>2013</year>): <fpage>1</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jocd16707-cit-0014">
<string-name>
<given-names>S.</given-names>
<surname>Chu</surname>
</string-name>, <string-name>
<given-names>D. P.</given-names>
<surname>Foulad</surname>
</string-name>, and <string-name>
<given-names>N.</given-names>
<surname>Atanaskova</surname>
</string-name>, &#x0201c;<article-title>Safety Profile for Microneedling: A Systematic Review</article-title>,&#x0201d; <source>Dermatologic Surgery</source>
<volume>47</volume>, no. <issue>9</issue> (<year>2021</year>): <fpage>1249</fpage>&#x02013;<lpage>1254</lpage>.<pub-id pub-id-type="pmid">34448760</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jocd16707-cit-0015">
<string-name>
<given-names>X.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Xiao</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Cen</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Xiao</surname>
</string-name>, &#x0201c;<article-title>Research Hotspot and Trend of Microneedles in Biomedical Field: A Bibliometric Analysis From 2011 to 2020</article-title>,&#x0201d; <source>Burns</source>
<volume>48</volume>, no. <issue>4</issue> (<year>2022</year>): <fpage>959</fpage>&#x02013;<lpage>972</lpage>.<pub-id pub-id-type="pmid">35504768</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jocd16707-cit-0016">
<string-name>
<given-names>E. V.</given-names>
<surname>de Andrade Lima</surname>
</string-name>, <string-name>
<given-names>L. M.</given-names>
<surname>de Andrade</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Takano</surname>
</string-name>, &#x0201c;<article-title>Microneedling: Experimental Study and Classification of the Resulting Injury</article-title>,&#x0201d; <source>Surgical and Cosmetic Dermatology</source>
<volume>5</volume>, no. <issue>2</issue> (<year>2013</year>): <fpage>110</fpage>&#x02013;<lpage>114</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jocd16707-cit-0017">
<string-name>
<given-names>P.</given-names>
<surname>Baker</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Radi</surname>
</string-name>, <string-name>
<given-names>S. B.</given-names>
<surname>Moll</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Jules</surname>
</string-name>, and <string-name>
<given-names>J. L.</given-names>
<surname>Arbiser</surname>
</string-name>, &#x0201c;<article-title>Skin Barrier Function: The Interplay of Physical, Chemical, and Immunologic Properties</article-title>,&#x0201d; <source>Cells&#x02010;Basel</source>
<volume>12</volume>, no. <issue>23</issue> (<year>2023</year>): <fpage>2745</fpage>.</mixed-citation></ref><ref id="jocd16707-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jocd16707-cit-0018">
<string-name>
<given-names>L.</given-names>
<surname>Dsouza</surname>
</string-name>, <string-name>
<given-names>V. M.</given-names>
<surname>Ghate</surname>
</string-name>, and <string-name>
<given-names>S. A.</given-names>
<surname>Lewis</surname>
</string-name>, &#x0201c;<article-title>Derma Rollers in Therapy: The Transition From Cosmetics to Transdermal Drug Delivery</article-title>,&#x0201d; <source>Biomedical Microdevices</source>
<volume>22</volume>, no. <issue>4</issue> (<year>2020</year>): <fpage>77</fpage>.<pub-id pub-id-type="pmid">33104926</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jocd16707-cit-0019">
<string-name>
<given-names>D.</given-names>
<surname>Fernandes</surname>
</string-name>, &#x0201c;<article-title>Minimally Invasive Percutaneous Collagen Induction</article-title>,&#x0201d; <source>Oral and Maxillofacial Surgery Clinics</source>
<volume>17</volume>, no. <issue>1</issue> (<year>2005</year>): <fpage>51</fpage>&#x02013;<lpage>63</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0020"><label>20</label><mixed-citation publication-type="book" id="jocd16707-cit-0020">
<string-name>
<given-names>B.</given-names>
<surname>Eckes</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Krieg</surname>
</string-name>, and <string-name>
<given-names>C. M.</given-names>
<surname>Niessen</surname>
</string-name>, <source>Biology of the Skin</source>, eds. <person-group person-group-type="editor">
<string-name>
<given-names>T.</given-names>
<surname>Krieg</surname>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<given-names>D. R.</given-names>
<surname>Bickers</surname>
</string-name>
</person-group>, and <person-group person-group-type="editor">
<string-name>
<given-names>Y.</given-names>
<surname>Miyachi</surname>
</string-name>
</person-group> (<publisher-loc>London</publisher-loc>: <publisher-name>Parthenon publishing groups</publisher-name>, <year>2010</year>), <fpage>3</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jocd16707-cit-0021">
<string-name>
<given-names>M. C.</given-names>
<surname>Aust</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Reimers</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Gohritz</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Percutaneous Collagen Induction. Scarless Skin Rejuvenation: Fact or Fiction?</article-title>,&#x0201d; <source>Clinical and Experimental Dermatology</source>
<volume>35</volume>, no. <issue>4</issue> (<year>2010</year>): <fpage>437</fpage>&#x02013;<lpage>439</lpage>.<pub-id pub-id-type="pmid">20337652</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jocd16707-cit-0022">
<string-name>
<given-names>D. P.</given-names>
<surname>Cassiano</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Esp&#x000f3;sito</surname>
</string-name>, <string-name>
<given-names>K. M.</given-names>
<surname>Hassun</surname>
</string-name>, <string-name>
<given-names>E. V.</given-names>
<surname>Lima</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Bagatin</surname>
</string-name>, and <string-name>
<given-names>H. A.</given-names>
<surname>Miot</surname>
</string-name>, &#x0201c;<article-title>Early Clinical and Histological Changes Induced by Microneedling in Facial Melasma: A Pilot Study</article-title>,&#x0201d; <source>Indian Journal of Dermatology, Venereology and Leprology</source>
<volume>85</volume>, no. <issue>6</issue> (<year>2019</year>): <fpage>638</fpage>&#x02013;<lpage>641</lpage>.<pub-id pub-id-type="pmid">31607716</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jocd16707-cit-0023">
<string-name>
<given-names>N. A.</given-names>
<surname>Taher</surname>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>El&#x02010;Sayed</surname>
</string-name>, and <string-name>
<given-names>H. A.</given-names>
<surname>Bessar</surname>
</string-name>, &#x0201c;<article-title>Efficacy of Skin Needling Device Versus Placebo in Treatment of Melasma</article-title>,&#x0201d; <source>Egyptian Journal of Hospital Medicine</source>
<volume>85</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>2968</fpage>&#x02013;<lpage>2972</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jocd16707-cit-0024">
<string-name>
<given-names>B.</given-names>
<surname>Hochman</surname>
</string-name>, <string-name>
<given-names>R. F.</given-names>
<surname>Locali</surname>
</string-name>, <string-name>
<given-names>P. K.</given-names>
<surname>Matsuoka</surname>
</string-name>, and <string-name>
<given-names>L. M.</given-names>
<surname>Ferreira</surname>
</string-name>, &#x0201c;<article-title>Intralesional Triamcinolone Acetonide for Keloid Treatment: A Systematic Review</article-title>,&#x0201d; <source>Aesthetic Plastic Surgery</source>
<volume>32</volume>, no. <issue>4</issue> (<year>2008</year>): <fpage>705</fpage>&#x02013;<lpage>709</lpage>.<pub-id pub-id-type="pmid">18418647</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jocd16707-cit-0025">
<string-name>
<given-names>X.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Zhu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Can Microneedle Fractional Radiofrequency System Treatment Impair the Skin Barrier Function in Chinese Patients? A Prospective Clinical Trial</article-title>,&#x0201d; <source>Dermatologic Therapy</source>
<volume>12</volume>, no. <issue>10</issue> (<year>2022</year>): <fpage>2371</fpage>&#x02013;<lpage>2382</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jocd16707-cit-0026">
<string-name>
<given-names>J. R.</given-names>
<surname>Chao</surname>
</string-name>, <string-name>
<given-names>J. P.</given-names>
<surname>Porter</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Hessler</surname>
</string-name>, &#x0201c;<article-title>Cosmetic Treatments With Energy&#x02010;Based Devices in Skin of Color</article-title>,&#x0201d; <source>Facial Plastic Surgery</source>
<volume>39</volume>, no. <issue>5</issue> (<year>2023</year>): <fpage>496</fpage>&#x02013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">37557909</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jocd16707-cit-0027">
<string-name>
<given-names>G. R.</given-names>
<surname>Ahn</surname>
</string-name>, <string-name>
<given-names>Y. N.</given-names>
<surname>Jang</surname>
</string-name>, <string-name>
<given-names>S. Y.</given-names>
<surname>Lee</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Full&#x02010;Thickness Skin Rejuvenation by a Novel Dual&#x02010;Length Microneedle Radiofrequency Device: A Proof&#x02010;Of&#x02010;Concept Study Using Human Skin</article-title>,&#x0201d; <source>Lasers in Surgery and Medicine</source>
<volume>55</volume>, no. <issue>8</issue> (<year>2023</year>): <fpage>758</fpage>&#x02013;<lpage>768</lpage>.<pub-id pub-id-type="pmid">37548075</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jocd16707-cit-0028">
<string-name>
<given-names>Y.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Liang</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Chen</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Combined Microfocused Ultrasound and Delicate Pulsed Light for Facial Rejuvenation: A Prospective, Randomized, and Split&#x02010;Face Study</article-title>,&#x0201d; <source>Lasers in Surgery and Medicine</source>
<volume>56</volume>, no. <issue>4</issue> (<year>2024</year>): <fpage>346</fpage>&#x02013;<lpage>354</lpage>.<pub-id pub-id-type="pmid">38462706</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jocd16707-cit-0029">
<string-name>
<given-names>H. J.</given-names>
<surname>Han</surname>
</string-name>, <string-name>
<given-names>J. C.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>Y. J.</given-names>
<surname>Park</surname>
</string-name>, and <string-name>
<given-names>H. Y.</given-names>
<surname>Kang</surname>
</string-name>, &#x0201c;<article-title>Targeting the Dermis for Melasma Maintenance Treatment</article-title>,&#x0201d; <source>Scientific Reports</source>
<volume>14</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>949</fpage>.<pub-id pub-id-type="pmid">38200171</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jocd16707-cit-0030">
<string-name>
<given-names>O.</given-names>
<surname>Markowitz</surname>
</string-name>, &#x0201c;<article-title>Vascular Density Changes After Treatment With A Bipolar Radiofrequency System Incorporating A Novel Applicator With 3&#x02010;IN&#x02010;1 Depth Ultra&#x02010;Thin Microneedle</article-title>,&#x0201d; <source>Lasers in Surgery and Medicine</source>
<volume>55</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>S84</fpage>&#x02013;<lpage>S85</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jocd16707-cit-0031">
<string-name>
<given-names>T.</given-names>
<surname>Passeron</surname>
</string-name>, &#x0201c;<article-title>Melasma Pathogenesis and Influencing Factors&#x02014;An Overview of the Latest Research</article-title>,&#x0201d; <source>Journal of the European Academy of Dermatology and Venereology</source>
<volume>27</volume>, no. <issue>S1</issue> (<year>2013</year>): <fpage>5</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">23205539</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jocd16707-cit-0032">
<string-name>
<given-names>Y.</given-names>
<surname>Zhu</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Song</surname>
</string-name>, and <string-name>
<given-names>W.</given-names>
<surname>Xiang</surname>
</string-name>, &#x0201c;<article-title>Comparative Study of Melasma in Patients Before and After Treatment Based on Lipomics</article-title>,&#x0201d; <source>Lipids in Health and Disease</source>
<volume>23</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>138</fpage>.<pub-id pub-id-type="pmid">38734619</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jocd16707-cit-0033">
<string-name>
<given-names>A.</given-names>
<surname>Kusumawardani</surname>
</string-name>, <string-name>
<given-names>A. R.</given-names>
<surname>Paramitasari</surname>
</string-name>, <string-name>
<given-names>S. R.</given-names>
<surname>Dewi</surname>
</string-name>, and <string-name>
<given-names>A. I.</given-names>
<surname>Betaubun</surname>
</string-name>, &#x0201c;<article-title>The Application of Liposomal Azelaic Acid, 4&#x02010;n Butyl Resorcinol and Retinol Serum Enhanced by Microneedling for Treatment of Malar Pattern Melasma: A Case Series</article-title>,&#x0201d; <source>Dermatology Reports</source>
<volume>11</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>139</fpage>&#x02013;<lpage>141</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jocd16707-cit-0034">
<string-name>
<given-names>C.</given-names>
<surname>Bergmann</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Pochmann</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Bergmann</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Use of Retinoic Acid in Association With Microneedling in the Treatment of Epidermal Melasma: Efficacy and Oxidative Stress Parameters</article-title>,&#x0201d; <source>Archives of Dermatological Research</source>
<volume>313</volume>, no. <issue>8</issue> (<year>2021</year>): <fpage>695</fpage>&#x02013;<lpage>704</lpage>.<pub-id pub-id-type="pmid">32978675</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jocd16707-cit-0035">
<string-name>
<given-names>A.</given-names>
<surname>Farag</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Hammam</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Alnaidany</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Methimazole in the Treatment of Melasma: A Clinical and Dermascopic Study</article-title>,&#x0201d; <source>Journal of Clinical and Aesthetic Dermatology</source>
<volume>14</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>14</fpage>&#x02013;<lpage>20</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jocd16707-cit-0036">
<string-name>
<given-names>M.</given-names>
<surname>Mohamed</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>beshay</surname>
</string-name>, and <string-name>
<given-names>H. M.</given-names>
<surname>Assaf</surname>
</string-name>, &#x0201c;<article-title>Microneedling With Glutathione Versus Microneedling Alone in Treatment of Facial Melasma: Split&#x02010;Face Comparative Study</article-title>,&#x0201d; <source>Journal of Cosmetic Dermatology</source>
<volume>22</volume>, no. <issue>12</issue> (<year>2023</year>): <fpage>3379</fpage>&#x02013;<lpage>3386</lpage>.<pub-id pub-id-type="pmid">37313658</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jocd16707-cit-0037">
<string-name>
<given-names>C.</given-names>
<surname>Yan</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Xing</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Zhang</surname>
</string-name>, and <string-name>
<given-names>Y.</given-names>
<surname>Gao</surname>
</string-name>, &#x0201c;<article-title>Clinical Development and Evaluation of a Multi&#x02010;Component Dissolving Microneedle Patch for Skin Pigmentation Disorders</article-title>,&#x0201d; <source>Polymers</source>
<volume>15</volume>, no. <issue>15</issue> (<year>2023</year>): <fpage>3296</fpage>.<pub-id pub-id-type="pmid">37571190</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jocd16707-cit-0038">
<string-name>
<given-names>G.</given-names>
<surname>Fabbrocini</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>De Vita</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Fardella</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Skin Needling to Enhance Depigmenting Serum Penetration in the Treatment of Melasma</article-title>,&#x0201d; <source>Plastic Surgery International</source>
<volume>2011</volume>, no. <issue>1</issue> (<year>2011</year>): <fpage>1</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jocd16707-cit-0039">
<string-name>
<given-names>E. A.</given-names>
<surname>Lima</surname>
</string-name>, &#x0201c;<article-title>Microneedling in Facial Recalcitrant Melasma: Report of a Series of 22 Cases</article-title>,&#x0201d; <source>Anais Brasileiros de Dermatologia</source>
<volume>90</volume>, no. <issue>6</issue> (<year>2015</year>): <fpage>919</fpage>&#x02013;<lpage>921</lpage>.<pub-id pub-id-type="pmid">26734882</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jocd16707-cit-0040">
<string-name>
<given-names>E.</given-names>
<surname>Lima</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Lima</surname>
</string-name>, <string-name>
<given-names>M. P.</given-names>
<surname>Paix&#x000e3;o</surname>
</string-name>, and <string-name>
<given-names>H. A.</given-names>
<surname>Miot</surname>
</string-name>, &#x0201c;<article-title>Assessment of the Effects of Skin Microneedling as Adjuvant Therapy for Facial Melasma: A Pilot Study</article-title>,&#x0201d; <source>BMC Dermatology</source>
<volume>17</volume>, no. <issue>1</issue> (<year>2017</year>): <fpage>14</fpage>.<pub-id pub-id-type="pmid">29183309</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jocd16707-cit-0041">
<string-name>
<given-names>J. F.</given-names>
<surname>Ram&#x000ed;rez&#x02010;Oliveros</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>de Abreu</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Tamler</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Vilhena</surname>
</string-name>, and <string-name>
<given-names>M. H.</given-names>
<surname>de Barros</surname>
</string-name>, &#x0201c;<article-title>Microneedling With Drug Delivery (Hydroquinone 4% Serum) as an Adjuvant Therapy for Recalcitrant Melasma</article-title>,&#x0201d; <source>Skinmed</source>
<volume>18</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>38</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">32167455</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jocd16707-cit-0042">
<string-name>
<given-names>S. S.</given-names>
<surname>Bosamiya</surname>
</string-name> and <string-name>
<given-names>S. M.</given-names>
<surname>Jain</surname>
</string-name>, &#x0201c;<article-title>A Pilot Study to Compare Therapeutic Efficacy and Safety of Combined Treatment of Skin Microneedling and Depigmenting Cream Versus Depigmenting Cream Alone in Facial Melasma at Tertiary Care Center</article-title>,&#x0201d; <source>Journal of Cutaneous and Aesthetic Surgery</source>
<volume>14</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>156</fpage>&#x02013;<lpage>159</lpage>.<pub-id pub-id-type="pmid">34566356</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="jocd16707-cit-0043">
<string-name>
<given-names>L.</given-names>
<surname>Budamakuntla</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Loganathan</surname>
</string-name>, <string-name>
<given-names>D. H.</given-names>
<surname>Suresh</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A Randomised, Open&#x02010;Label, Comparative Study of Tranexamic Acid Microinjections and Tranexamic Acid With Microneedling in Patients With Melasma</article-title>,&#x0201d; <source>Journal of Cutaneous and Aesthetic Surgery</source>
<volume>6</volume>, no. <issue>3</issue> (<year>2013</year>): <fpage>139</fpage>&#x02013;<lpage>143</lpage>.<pub-id pub-id-type="pmid">24163529</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="jocd16707-cit-0044">
<string-name>
<given-names>Y.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Ma</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Juliandri</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Efficacy of Functional Microarray of Microneedles Combined With Topical Tranexamic Acid for Melasma: A Randomized, Self&#x02010;Controlled, Split&#x02010;Face Study</article-title>,&#x0201d; <source>Medicine (Baltimore)</source>
<volume>96</volume>, no. <issue>19</issue> (<year>2017</year>): <elocation-id>e6897</elocation-id>.<pub-id pub-id-type="pmid">28489798</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="jocd16707-cit-0045">
<string-name>
<given-names>L. P. P. G.</given-names>
<surname>Saraiva</surname>
</string-name>, <string-name>
<given-names>M. B.</given-names>
<surname>de Nascimento</surname>
</string-name>, <string-name>
<given-names>A. A.</given-names>
<surname>Filippo</surname>
</string-name>, and <string-name>
<given-names>P. R.</given-names>
<surname>de Gusm&#x000e3;o</surname>
</string-name>, &#x0201c;<article-title>Treatment of Facial Melasma With Robotic Microneedling Associated to Drug Delivery of Tranexamic Acid</article-title>,&#x0201d; <source>Surgical and Cosmetic Dermatology</source>
<volume>10</volume>, no. <issue>4</issue> (<year>2018</year>): <fpage>333</fpage>&#x02013;<lpage>339</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="jocd16707-cit-0046">
<string-name>
<given-names>F. Y.</given-names>
<surname>Saleh</surname>
</string-name>, <string-name>
<given-names>E. S.</given-names>
<surname>Abdel&#x02010;Azim</surname>
</string-name>, <string-name>
<given-names>M. H.</given-names>
<surname>Ragaie</surname>
</string-name>, and <string-name>
<given-names>M. G.</given-names>
<surname>Guendy</surname>
</string-name>, &#x0201c;<article-title>Topical Tranexamic Acid With Microneedling Versus Microneedling Alone in Treatment of Melasma: Clinical, Histopathologic, and Immunohistochemical Study</article-title>,&#x0201d; <source>Journal of the Egyptian Women's Dermatologic Society</source>
<volume>16</volume>, no. <issue>2</issue> (<year>2019</year>): <fpage>89</fpage>&#x02013;<lpage>96</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="jocd16707-cit-0047">
<string-name>
<given-names>V.</given-names>
<surname>Wali</surname>
</string-name> and <string-name>
<given-names>H.</given-names>
<surname>Parwani</surname>
</string-name>, &#x0201c;<article-title>Comparative Study of Oral Tranexamic Acid and Triple Combination Versus Tranexamic Acid Through Microneedling in Patients of Melisma</article-title>,&#x0201d; <source>International Journal of Research in Dermatology</source>
<volume>5</volume>, no. <issue>3</issue> (<year>2019</year>): <fpage>537</fpage>&#x02013;<lpage>541</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="jocd16707-cit-0048">
<string-name>
<given-names>A.</given-names>
<surname>Kaur</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Bhalla</surname>
</string-name>, <string-name>
<given-names>G. P.</given-names>
<surname>Thami</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Kaur</surname>
</string-name>, &#x0201c;<article-title>Clinical Efficacy of Topical Tranexamic Acid With Microneedling in Melasma</article-title>,&#x0201d; <source>Journal of the Dermatology Nurses' Association</source>
<volume>12</volume>, no. <issue>2</issue> (<year>2020</year>): <fpage>e96</fpage>&#x02013;<lpage>e101</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="jocd16707-cit-0049">
<string-name>
<given-names>D.</given-names>
<surname>Cassiano</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Esposito</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Hassun</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Efficacy and Safety of Microneedling and Oral Tranexamic Acid in the Treatment of Facial Melasma in Women: An Open, Evaluator&#x02010;Blinded, Randomized Clinical Trial</article-title>,&#x0201d; <source>Journal of the American Academy of Dermatology</source>
<volume>83</volume>, no. <issue>4</issue> (<year>2020</year>): <fpage>1176</fpage>&#x02013;<lpage>1178</lpage>.<pub-id pub-id-type="pmid">32035945</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="jocd16707-cit-0050">
<string-name>
<given-names>M. S.</given-names>
<surname>Shamsi</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Mozayyeni</surname>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Shamsi</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Aflatoonian</surname>
</string-name>, &#x0201c;<article-title>Efficacy of Microneedling Plus Topical 4% Tranexamic Acid Solution vs 4% Hydroquinone in the Treatment of Melasma: A Single&#x02010;Blind Randomized Clinical Trial</article-title>,&#x0201d; <source>Journal of Cosmetic Dermatology</source>
<volume>19</volume>, no. <issue>11</issue> (<year>2020</year>): <fpage>2906</fpage>&#x02013;<lpage>2911</lpage>.<pub-id pub-id-type="pmid">32406162</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="jocd16707-cit-0051">
<string-name>
<given-names>H. M.</given-names>
<surname>Ebrahim</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Said Abdelshafy</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Khattab</surname>
</string-name>, and <string-name>
<given-names>K.</given-names>
<surname>Gharib</surname>
</string-name>, &#x0201c;<article-title>Tranexamic Acid for Melasma Treatment: A Split&#x02010;Face Study</article-title>,&#x0201d; <source>Dermatologic Surgery</source>
<volume>46</volume>, no. <issue>11</issue> (<year>2020</year>): <fpage>e102</fpage>&#x02013;<lpage>e107</lpage>.<pub-id pub-id-type="pmid">32701529</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="jocd16707-cit-0052">
<string-name>
<given-names>A. A.</given-names>
<surname>Aly</surname>
</string-name>, <string-name>
<given-names>R. E.</given-names>
<surname>AbdElMaksoud</surname>
</string-name>, and <string-name>
<given-names>I.</given-names>
<surname>Ismail</surname>
</string-name>, &#x0201c;<article-title>Tranexamic Acid Versus Topical Mesolightening Mixture Using the Dermaroller in the Treatment of Melisma</article-title>,&#x0201d; <source>Egyptian Journal of Dermatology and Venerology</source>
<volume>40</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>45</fpage>&#x02013;<lpage>52</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="jocd16707-cit-0053">
<string-name>
<given-names>X.</given-names>
<surname>Xing</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Jin</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Zhang</surname>
</string-name>, and <string-name>
<given-names>L.</given-names>
<surname>Xiang</surname>
</string-name>, &#x0201c;<article-title>The Efficacy and Safety of Topical Tranexamic Acid (Liposomal or Lotion With Microneedling) Versus Conventional Hydroquinone in the Treatment of Melasma</article-title>,&#x0201d; <source>Journal of Cosmetic Dermatology</source>
<volume>19</volume>, no. <issue>12</issue> (<year>2020</year>): <fpage>3238</fpage>&#x02013;<lpage>3244</lpage>.<pub-id pub-id-type="pmid">33091202</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="jocd16707-cit-0054">
<string-name>
<given-names>B.</given-names>
<surname>Hassan</surname>
</string-name>, <string-name>
<given-names>L. M.</given-names>
<surname>Malik</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Rashid</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Anum</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Hayat</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Hanif</surname>
</string-name>, &#x0201c;<article-title>Effect of Combination of Microneedling With Tranexamic Acid on Modified MASI Score in Patients of Melasma</article-title>,&#x0201d; <source>Journal of Pakistan Association of Dermatologists</source>
<volume>31</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>23</fpage>&#x02013;<lpage>27</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="jocd16707-cit-0055">
<string-name>
<given-names>M. S.</given-names>
<surname>Zaky</surname>
</string-name>, <string-name>
<given-names>Z. M.</given-names>
<surname>Obaid</surname>
</string-name>, <string-name>
<given-names>E. A.</given-names>
<surname>Khalil</surname>
</string-name>, and <string-name>
<given-names>M. L.</given-names>
<surname>Elsaie</surname>
</string-name>, &#x0201c;<article-title>Microneedling&#x02010;Assisted Topical Tranexamic Acid Solution Versus 4% Hydroquinone for Treating Melasma: A Split&#x02010;Face Randomized Study</article-title>,&#x0201d; <source>Journal of Cosmetic Dermatology</source>
<volume>20</volume>, no. <issue>12</issue> (<year>2021</year>): <fpage>4011</fpage>&#x02013;<lpage>4016</lpage>.<pub-id pub-id-type="pmid">34525492</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="jocd16707-cit-0056">
<string-name>
<given-names>D.</given-names>
<surname>Kuster</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Orso</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Marioto</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Randomized, Double&#x02010;Blind, Placebo&#x02010;Controlled Split&#x02010;Face Trial of the Efficacy of Tranexamic Acid by Drug Delivery Through Microneedling in the Treatment of Melasma</article-title>,&#x0201d; <source>Journal of Cosmetic Dermatology</source>
<volume>20</volume>, no. <issue>12</issue> (<year>2021</year>): <fpage>4005</fpage>&#x02013;<lpage>4010</lpage>.<pub-id pub-id-type="pmid">34077619</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="jocd16707-cit-0057">
<string-name>
<given-names>M.</given-names>
<surname>Susmitha</surname>
</string-name>, <string-name>
<given-names>K. S.</given-names>
<surname>Divya</surname>
</string-name>, <string-name>
<given-names>B. V.</given-names>
<surname>Ramachandra</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Subbarao</surname>
</string-name>, &#x0201c;<article-title>Evaluation of Therapeutic Efficacy of Tranexemic Acid Compared to Kligman Formula in the Management of Melasma</article-title>,&#x0201d; <source>IP Indian Journal of Clinical and Experimental Dermatology</source>
<volume>8</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>124</fpage>&#x02013;<lpage>131</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="jocd16707-cit-0058">
<string-name>
<given-names>J.</given-names>
<surname>Batra</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Brar</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Kumar</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Arora</surname>
</string-name>, &#x0201c;<article-title>Tranexamic Acid in Melasma: Comparative Evaluation of Therapeutic Efficacy of Oral Tranexamic Acid Versus Its Transepidermal Administration</article-title>,&#x0201d; <source>Journal of Cutaneous and Aesthetic Surgery</source>
<volume>15</volume>, no. <issue>4</issue> (<year>2022</year>): <fpage>394</fpage>&#x02013;<lpage>399</lpage>.<pub-id pub-id-type="pmid">37035597</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="jocd16707-cit-0059">
<string-name>
<given-names>D. P.</given-names>
<surname>Cassiano</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Esp&#x000f3;sito</surname>
</string-name>, <string-name>
<given-names>K. M.</given-names>
<surname>Hassun</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Histological Changes in Facial Melasma After Treatment With Triple Combination Cream With or Without Oral Tranexamic Acid and/or Microneedling: A Randomised Clinical Trial</article-title>,&#x0201d; <source>Indian Journal of Dermatology, Venereology and Leprology</source>
<volume>88</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>761</fpage>&#x02013;<lpage>770</lpage>.<pub-id pub-id-type="pmid">35389028</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="jocd16707-cit-0060">
<string-name>
<given-names>N.</given-names>
<surname>Poostiyan</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Alizadeh</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Shahmoradi</surname>
</string-name>, and <string-name>
<given-names>N. F.</given-names>
<surname>Fatemi</surname>
</string-name>, &#x0201c;<article-title>Tranexamic Acid Microinjections Versus Tranexamic Acid Mesoneedling in the Treatment of Facial Melasma: A Randomized Assessor&#x02010;Blind Split&#x02010;Face Controlled Trial</article-title>,&#x0201d; <source>Journal of Cosmetic Dermatology</source>
<volume>22</volume>, no. <issue>4</issue> (<year>2023</year>): <fpage>1238</fpage>&#x02013;<lpage>1244</lpage>.<pub-id pub-id-type="pmid">36606390</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="jocd16707-cit-0061">
<string-name>
<given-names>R.</given-names>
<surname>Yu</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Fei</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>BoZhi</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>XinDong</surname>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Yong</surname>
</string-name>, &#x0201c;<article-title>Clinical Observation of Polylactic Acid Microneedles Combined With Tranexamic Acid Essence in the Treatment of Melasma</article-title>,&#x0201d; <source>Beijing Huagong Daxue Xuebao (Ziran Kexueban)/Journal of Beijing University of Chemical Technology (Natural Science Edition)</source>
<volume>50</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>72</fpage>&#x02013;<lpage>78</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="jocd16707-cit-0062">
<string-name>
<given-names>W.</given-names>
<surname>Zheng</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Tian</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Ke</surname>
</string-name>, &#x0201c;<article-title>Roller Microneedle Combined With Tranexamic Acid Solution in Treating Melasma</article-title>,&#x0201d; <source>Journal of Visualized Experiments: JoVE</source>
<volume>203</volume>, <pub-id pub-id-type="doi">10.3791/66015</pub-id>. 19 Jan 2024.</mixed-citation></ref><ref id="jocd16707-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="jocd16707-cit-0063">
<string-name>
<given-names>Z.</given-names>
<surname>Yan</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>S. U.</given-names>
<surname>Fei</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Clinical Observation on the Efficacy of Microneedle Roller Combined With Topical Medicines for Melasma</article-title>,&#x0201d; <source>Chinese Journal of Dermatovenereology</source> no. <issue>31</issue> (<year>2017</year>): <fpage>203</fpage>.</mixed-citation></ref><ref id="jocd16707-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="jocd16707-cit-0064">
<string-name>
<given-names>E.</given-names>
<surname>Ismail</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Patsatsi</surname>
</string-name>, <string-name>
<given-names>E. W.</given-names>
<surname>Abd</surname>
</string-name>, and <string-name>
<given-names>E.</given-names>
<surname>Nada</surname>
</string-name>, &#x0201c;<article-title>Efficacy of Microneedling With Topical Vitamin C in the Treatment of Melasma</article-title>,&#x0201d; <source>Journal of Cosmetic Dermatology</source>
<volume>18</volume>, no. <issue>5</issue> (<year>2019</year>): <fpage>1342</fpage>&#x02013;<lpage>1347</lpage>.<pub-id pub-id-type="pmid">30770637</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="jocd16707-cit-0065">
<string-name>
<given-names>S.</given-names>
<surname>Farshi</surname>
</string-name> and <string-name>
<given-names>P.</given-names>
<surname>Mansouri</surname>
</string-name>, &#x0201c;<article-title>Study of Efficacy of Microneedling and Mesoneedling in the Treatment of Epidermal Melasma: A Pilot Trial</article-title>,&#x0201d; <source>Journal of Cosmetic Dermatology</source>
<volume>19</volume>, no. <issue>5</issue> (<year>2020</year>): <fpage>1093</fpage>&#x02013;<lpage>1098</lpage>.<pub-id pub-id-type="pmid">32196865</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="jocd16707-cit-0066">
<string-name>
<given-names>A.</given-names>
<surname>Menon</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Eram</surname>
</string-name>, <string-name>
<given-names>P. R.</given-names>
<surname>Kamath</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Goel</surname>
</string-name>, and <string-name>
<given-names>A. M.</given-names>
<surname>Babu</surname>
</string-name>, &#x0201c;<article-title>A Split Face Comparative Study of Safety and Efficacy of Microneedling With Tranexamic Acid Versus Microneedling With Vitamin C in the Treatment of Melasma</article-title>,&#x0201d; <source>Indian Dermatology Online Journal</source>
<volume>11</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>41</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">32055507</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="jocd16707-cit-0067">
<string-name>
<given-names>A. I.</given-names>
<surname>Tahoun</surname>
</string-name>, <string-name>
<given-names>W. Z.</given-names>
<surname>Mostafa</surname>
</string-name>, and <string-name>
<given-names>M. A.</given-names>
<surname>Amer</surname>
</string-name>, &#x0201c;<article-title>Dermoscopic Evaluation of Tranexamic Acid Versus Vitamin C, With Microneedling in the Treatment of Melasma: A Comparative, Split&#x02010;Face, Single&#x02010;Blinded Study</article-title>,&#x0201d; <source>Journal of Dermatological Treatment</source>
<volume>33</volume>, no. <issue>3</issue> (<year>2022</year>): <fpage>1623</fpage>&#x02013;<lpage>1629</lpage>.<pub-id pub-id-type="pmid">33393842</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="jocd16707-cit-0068">
<string-name>
<given-names>Y.</given-names>
<surname>El</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Doghaim</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>El</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>El</surname>
</string-name>, and <string-name>
<given-names>S. A.</given-names>
<surname>Hawwam</surname>
</string-name>, &#x0201c;<article-title>Efficacy and Safety of Tranexamic Acid Versus Vitamin C After Microneedling in Treatment of Melasma: Clinical and Dermoscopic Study</article-title>,&#x0201d; <source>Journal of Cosmetic Dermatology</source>
<volume>21</volume>, no. <issue>7</issue> (<year>2022</year>): <fpage>2817</fpage>&#x02013;<lpage>2825</lpage>.<pub-id pub-id-type="pmid">34699671</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="jocd16707-cit-0069">
<string-name>
<given-names>M. H.</given-names>
<surname>Raza</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Iftikhar</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Anwar</surname>
</string-name>, <string-name>
<given-names>A. A.</given-names>
<surname>Mashhood</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Tariq</surname>
</string-name>, and <string-name>
<given-names>M. A. B.</given-names>
<surname>Hamid</surname>
</string-name>, &#x0201c;<article-title>Split&#x02010;Face Comparative Analysis of Micro&#x02010;Needling With Tranexamic Acid vs Vitamin C Serum in Melasma</article-title>,&#x0201d; <source>Journal of Ayub Medical College, Abbottabad: JAMC</source>
<volume>34</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>169</fpage>&#x02013;<lpage>172</lpage>.<pub-id pub-id-type="pmid">35466647</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="jocd16707-cit-0070">
<string-name>
<given-names>S.</given-names>
<surname>Gul</surname>
</string-name>, <string-name>
<given-names>S. A. A.</given-names>
<surname>Gardezi</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Arshad</surname>
</string-name>, <string-name>
<given-names>T. J.</given-names>
<surname>Ahmad</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Aman</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Shaukat</surname>
</string-name>, &#x0201c;<article-title>Microneedling With Topical Ascorbic Acid in the Treatment of Melasma</article-title>,&#x0201d; <source>Journal of Pakistan Association of Dermatologists</source>
<volume>33</volume>, no. <issue>2</issue> (<year>2023</year>): <fpage>547</fpage>&#x02013;<lpage>552</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="jocd16707-cit-0071">
<string-name>
<given-names>E.</given-names>
<surname>Hofny</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Hussein</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Ghazally</surname>
</string-name>, <string-name>
<given-names>A. M.</given-names>
<surname>Ahmed</surname>
</string-name>, and <string-name>
<given-names>A. A.</given-names>
<surname>Abdel&#x02010;Motaleb</surname>
</string-name>, &#x0201c;<article-title>Increased Expression of TGF&#x02010;&#x003b2; Protein in the Lesional Skins of Melasma Patients Following Treatment With Platelet&#x02010;Rich Plasma</article-title>,&#x0201d; <source>Journal of Cosmetic and Laser Therapy</source>
<volume>21</volume>, no. <issue>7&#x02013;8</issue> (<year>2019</year>): <fpage>382</fpage>&#x02013;<lpage>389</lpage>.<pub-id pub-id-type="pmid">31554441</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="jocd16707-cit-0072">
<string-name>
<given-names>E.</given-names>
<surname>Hofny</surname>
</string-name>, <string-name>
<given-names>A. A.</given-names>
<surname>Abdel&#x02010;Motaleb</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Ghazally</surname>
</string-name>, <string-name>
<given-names>A. M.</given-names>
<surname>Ahmed</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Hussein</surname>
</string-name>, &#x0201c;<article-title>Platelet&#x02010;Rich Plasma Is a Useful Therapeutic Option in Melasma</article-title>,&#x0201d; <source>Journal of Dermatological Treatment</source>
<volume>30</volume>, no. <issue>4</issue> (<year>2019</year>): <fpage>396</fpage>&#x02013;<lpage>401</lpage>.<pub-id pub-id-type="pmid">30220226</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="jocd16707-cit-0073">
<string-name>
<given-names>A. S.</given-names>
<surname>Boparai</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Bhale</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Brar</surname>
</string-name>, &#x0201c;<article-title>Evaluation of Therapeutic Outcome of Transepidermal Administration of Platelet&#x02010;Rich Plasma With Microneedling in Melasma</article-title>,&#x0201d; <source>Dermatologic Therapy</source>
<volume>33</volume>, no. <issue>6</issue> (<year>2020</year>): <elocation-id>e14358</elocation-id>.<pub-id pub-id-type="pmid">32996654</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="jocd16707-cit-0074">
<string-name>
<given-names>K.</given-names>
<surname>Gharib</surname>
</string-name>, <string-name>
<given-names>F. F.</given-names>
<surname>Mostafa</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Ghonemy</surname>
</string-name>, &#x0201c;<article-title>Therapeutic Effect of Microneedling With Platelet&#x02010;Rich Plasma Versus Microneedling With Tranexamic Acid for Melasma</article-title>,&#x0201d; <source>Journal of Clinical and Aesthetic Dermatology</source>
<volume>14</volume>, no. <issue>8</issue> (<year>2021</year>): <fpage>44</fpage>&#x02013;<lpage>48</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="jocd16707-cit-0075">
<string-name>
<given-names>A. K.</given-names>
<surname>Panda</surname>
</string-name>, <string-name>
<given-names>A. K.</given-names>
<surname>Jena</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Panda</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Raj</surname>
</string-name>, and <string-name>
<given-names>I.</given-names>
<surname>Debata</surname>
</string-name>, &#x0201c;<article-title>Micro Needling vs Micro Needling Combined With Autologous Topical Platelet Rich Plasma in the Treatment of Melasma: A Prospective Randomized Comparative Study</article-title>,&#x0201d; <source>International Journal of Research</source>
<volume>8</volume> (<year>2022</year>): <fpage>78</fpage>.</mixed-citation></ref><ref id="jocd16707-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="jocd16707-cit-0076">
<string-name>
<given-names>P. S.</given-names>
<surname>Tekam</surname>
</string-name> and <string-name>
<given-names>V. A.</given-names>
<surname>Belgaumkar</surname>
</string-name>, &#x0201c;<article-title>Combination of Autologous Platelet Rich Plasma and Hydroquinone 4% Is More Effective Than Hydroquinone Alone in Treatment of Melasma: A Split&#x02010;Face Comparative Study</article-title>,&#x0201d; <source>Dermatologic Therapy</source>
<volume>35</volume>, no. <issue>11</issue> (<year>2022</year>): <elocation-id>e15761</elocation-id>.<pub-id pub-id-type="pmid">36068674</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="jocd16707-cit-0077">
<string-name>
<given-names>T.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Gao</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Wang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Stem Cell&#x02010;Derived Exosomes in the Treatment of Melasma and Its Percutaneous Penetration</article-title>,&#x0201d; <source>Lasers in Surgery and Medicine</source>
<volume>55</volume>, no. <issue>2</issue> (<year>2023</year>): <fpage>178</fpage>&#x02013;<lpage>189</lpage>.<pub-id pub-id-type="pmid">36573453</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="jocd16707-cit-0078">
<string-name>
<given-names>M.</given-names>
<surname>Gulfan</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Wanitphakdeedecha</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Wongdama</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Jantanapornchai</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Yan</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Rakchart</surname>
</string-name>, &#x0201c;<article-title>Efficacy and Safety of Using Noninsulated Microneedle Radiofrequency Alone Versus in Combination With Polynucleotides for the Treatment of Melasma: A Pilot Study</article-title>,&#x0201d; <source>Dermatology and Therapy</source>
<volume>12</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>1325</fpage>&#x02013;<lpage>1336</lpage>.<pub-id pub-id-type="pmid">35538360</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="jocd16707-cit-0079">
<string-name>
<given-names>M.</given-names>
<surname>Avcil</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Akman</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Klokkers</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Jeong</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>&#x000c7;elik</surname>
</string-name>, &#x0201c;<article-title>Clinical Efficacy of Dissolvable Microneedles Armed With Anti&#x02010;Melanogenic Compounds to Counter Hyperpigmentation</article-title>,&#x0201d; <source>Journal of Cosmetic Dermatology</source>
<volume>20</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>605</fpage>&#x02013;<lpage>614</lpage>.<pub-id pub-id-type="pmid">32692898</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="jocd16707-cit-0080">
<string-name>
<given-names>P.</given-names>
<surname>Ustuner</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Balevi</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Ozdemir</surname>
</string-name>, &#x0201c;<article-title>A Split&#x02010;Face, Investigator&#x02010;Blinded Comparative Study on the Efficacy and Safety of Q&#x02010;Switched Nd:YAG Laser Plus Microneedling With Vitamin C Versus Q&#x02010;Switched Nd:YAG Laser for the Treatment of Recalcitrant Melasma</article-title>,&#x0201d; <source>Journal of Cosmetic and Laser Therapy</source>
<volume>19</volume>, no. <issue>7</issue> (<year>2017</year>): <fpage>383</fpage>&#x02013;<lpage>390</lpage>.<pub-id pub-id-type="pmid">28657378</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="jocd16707-cit-0081">
<string-name>
<given-names>L.</given-names>
<surname>Quan</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Tang</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Tao</surname>
</string-name>, and <string-name>
<given-names>Z.</given-names>
<surname>Wang</surname>
</string-name>, &#x0201c;<article-title>Clinical Efficacy of Q&#x02010;Modulated Laser Combined With Compound Repair of Oligosaccharides in the Treatment of Melisma</article-title>,&#x0201d; <source>Chinese Journal of Plastic Surgery</source> no. <issue>35</issue> (<year>2019</year>): <fpage>1185</fpage>&#x02013;<lpage>1190</lpage>.</mixed-citation></ref><ref id="jocd16707-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="jocd16707-cit-0082">
<string-name>
<given-names>J. W.</given-names>
<surname>Jung</surname>
</string-name>, <string-name>
<given-names>W. O.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>H. R.</given-names>
<surname>Jung</surname>
</string-name>, <string-name>
<given-names>S. A.</given-names>
<surname>Kim</surname>
</string-name>, and <string-name>
<given-names>Y. W.</given-names>
<surname>Ryoo</surname>
</string-name>, &#x0201c;<article-title>A Face&#x02010;Split Study to Evaluate the Effects of Microneedle Radiofrequency With Q&#x02010;Switched Nd:YAG Laser for the Treatment of Melasma</article-title>,&#x0201d; <source>Annals of Dermatology</source>
<volume>31</volume>, no. <issue>2</issue> (<year>2019</year>): <fpage>133</fpage>&#x02013;<lpage>138</lpage>.<pub-id pub-id-type="pmid">33911561</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="jocd16707-cit-0083">
<string-name>
<given-names>H. H.</given-names>
<surname>Kwon</surname>
</string-name>, <string-name>
<given-names>S. C.</given-names>
<surname>Choi</surname>
</string-name>, <string-name>
<given-names>J. Y.</given-names>
<surname>Jung</surname>
</string-name>, and <string-name>
<given-names>G. H.</given-names>
<surname>Park</surname>
</string-name>, &#x0201c;<article-title>Combined Treatment of Melasma Involving Low&#x02010;Fluence Q&#x02010;Switched Nd:YAG Laser and Fractional Microneedling Radiofrequency</article-title>,&#x0201d; <source>Journal of Dermatological Treatment</source>
<volume>30</volume>, no. <issue>4</issue> (<year>2019</year>): <fpage>352</fpage>&#x02013;<lpage>356</lpage>.<pub-id pub-id-type="pmid">30160539</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="jocd16707-cit-0084">
<string-name>
<given-names>K. &#x000d6;.</given-names>
<surname>Karada&#x0011f;</surname>
</string-name> and <string-name>
<given-names>M.</given-names>
<surname>Borlu</surname>
</string-name>, &#x0201c;<article-title>Efficacy of the Combination of Q&#x02010;Switched Nd:YAG Laser and Microneedling for Melasma</article-title>,&#x0201d; <source>Journal of Cosmetic Dermatology</source>
<volume>20</volume>, no. <issue>3</issue> (<year>2021</year>): <fpage>769</fpage>&#x02013;<lpage>775</lpage>.<pub-id pub-id-type="pmid">32696614</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="jocd16707-cit-0085">
<string-name>
<given-names>B.</given-names>
<surname>Debasmita</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Raj</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Ishan</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Ipsita</surname>
</string-name>, &#x0201c;<article-title>A Prospective Randomized Controlled Trial of Q&#x02010;Switched Nd: YAG Laser With Topical 3% Tranexamic Acid (TA) Versus Microneedling With Topical 3% Tranexamic Acid (TA) in Treatment of Melasma</article-title>,&#x0201d; <source>Journal of Cosmetic Dermatology</source>
<volume>21</volume>, no. <issue>7</issue> (<year>2022</year>): <fpage>2801</fpage>&#x02013;<lpage>2807</lpage>.<pub-id pub-id-type="pmid">34636493</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="jocd16707-cit-0086">
<string-name>
<given-names>Y. I.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>D. W.</given-names>
<surname>Lee</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Synergistic Effect of 300&#x02009;&#x003bc;m Needle&#x02010;Depth Fractional Microneedling Radiofrequency on the Treatment of Senescence&#x02010;Induced Aging Hyperpigmentation of the Skin</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>22</volume>, no. <issue>14</issue> (<year>2021</year>): <fpage>7480</fpage>.<pub-id pub-id-type="pmid">34299100</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="jocd16707-cit-0087">
<string-name>
<given-names>K.</given-names>
<surname>Mekawy</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Sadek</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Seddeik</surname>
</string-name>, &#x0201c;<article-title>Micro&#x02010;Needling Versus Fractional Carbon Dioxide Laser for Delivery of Tranexamic Acid in the Treatment of Melasma: A Split&#x02010;Face Study</article-title>,&#x0201d; <source>Journal of Cosmetic Dermatology</source>
<volume>20</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>460</fpage>&#x02013;<lpage>465</lpage>.<pub-id pub-id-type="pmid">32562337</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="jocd16707-cit-0088">
<string-name>
<given-names>K. D. S.</given-names>
<surname>Mamdouh</surname>
</string-name>, <string-name>
<given-names>D. S.</given-names>
<surname>Hegab</surname>
</string-name>, <string-name>
<given-names>E. M. G.</given-names>
<surname>Mohamed</surname>
</string-name>, and <string-name>
<given-names>E. A.</given-names>
<surname>Ahmad</surname>
</string-name>, &#x0201c;<article-title>Efficacy and Safety of Topical Tranexamic Acid Alone or in Combination With Either Fractional Carbon Dioxide Laser or Microneedling for the Treatment of Melasma</article-title>,&#x0201d; <source>Dermatology Practical &#x00026; Conceptual</source>
<volume>13</volume>, no. <issue>3</issue> (<year>2023</year>): <elocation-id>e2023195</elocation-id>.<pub-id pub-id-type="pmid">37557109</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="jocd16707-cit-0089">
<string-name>
<given-names>E. R.</given-names>
<surname>Hofny</surname>
</string-name>, <string-name>
<given-names>A. A.</given-names>
<surname>Abdel&#x02010;Motaleb</surname>
</string-name>, <string-name>
<given-names>S. A.</given-names>
<surname>Hamed</surname>
</string-name>, and <string-name>
<given-names>H. O.</given-names>
<surname>Twisy</surname>
</string-name>, &#x0201c;<article-title>Trichloroacetic Acid With Microneedling Versus Trichloroacetic Acid Alone for Treating Melasma</article-title>,&#x0201d; <source>Dermatologic Surgery</source>
<volume>49</volume>, no. <issue>1</issue> (<year>2023</year>): <fpage>66</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">36533799</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="jocd16707-cit-0090">
<string-name>
<given-names>M. C.</given-names>
<surname>Aust</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Reimers</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Repenning</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Percutaneous Collagen Induction: Minimally Invasive Skin Rejuvenation Without Risk of Hyperpigmentation&#x02010;Fact or Fiction?</article-title>,&#x0201d; <source>Plastic and Reconstructive Surgery</source>
<volume>122</volume>, no. <issue>5</issue> (<year>2008</year>): <fpage>1553</fpage>&#x02013;<lpage>1563</lpage>.<pub-id pub-id-type="pmid">18971740</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="jocd16707-cit-0091">
<string-name>
<given-names>A.</given-names>
<surname>Bailey</surname>
</string-name>, <string-name>
<given-names>H. O.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>M. G.</given-names>
<surname>Tan</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Cheng</surname>
</string-name>, and <string-name>
<given-names>J. S.</given-names>
<surname>Dover</surname>
</string-name>, &#x0201c;<article-title>Microneedling as an Adjuvant to Topical Therapies for Melasma: A Systematic Review and Meta&#x02010;Analysis</article-title>,&#x0201d; <source>Journal of the American Academy of Dermatology</source>
<volume>86</volume>, no. <issue>4</issue> (<year>2022</year>): <fpage>797</fpage>&#x02013;<lpage>810</lpage>.<pub-id pub-id-type="pmid">33857549</pub-id>
</mixed-citation></ref><ref id="jocd16707-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="jocd16707-cit-0092">
<string-name>
<given-names>B. J.</given-names>
<surname>Park</surname>
</string-name>, <string-name>
<given-names>Y. J.</given-names>
<surname>Jung</surname>
</string-name>, <string-name>
<given-names>Y. S.</given-names>
<surname>Ro</surname>
</string-name>, <string-name>
<given-names>S. E.</given-names>
<surname>Chang</surname>
</string-name>, and <string-name>
<given-names>J. E.</given-names>
<surname>Kim</surname>
</string-name>, &#x0201c;<article-title>Therapeutic Effects of New Pulsed&#x02010;Type Microneedling Radiofrequency for Refractory Facial Pigmentary Disorders</article-title>,&#x0201d; <source>Dermatologic Surgery</source>
<volume>48</volume>, no. <issue>3</issue> (<year>2022</year>): <fpage>327</fpage>&#x02013;<lpage>333</lpage>.<pub-id pub-id-type="pmid">34999602</pub-id>
</mixed-citation></ref></ref-list></back></article>